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Executive Summary
Executive Summary: The subcutaneous Administration of Bortezomib Practice Guideline Project
Problem
Multiple myeloma is the second leading cause of hematological malignancies in the 
United States. Bortezomib is a chemotherapy agent effective in the treatment of all stages of 
multiple myeloma. Bortezomib administered by the subcutaneous (SC) route is as efficacious as 
the intravenous route. However, the literature does not describe how the drug was to be 
administered SC. A review of literature was inconclusive on how to administer SC injections and 
supported the need to describe how nurses are administering SC injections in order to develop 
practice guidelines.
The question guiding this evidence based project was: For oncology nurses in a network 
of community clinics will the development of a standardized guideline for the administration of 
SC bortezomib compared to absence of a standard guideline result in the implementation of a 
standard guideline.
Purpose
The purpose of this evidence based practice improvement project was to develop a 
practice guideline for administering SC bortezomib in a network of community oncology clinics.
Goal
The goal was to present the evidence based practice guideline for implementation at a 
network of oncology clinics.
Objectives
The objectives for this project included 1) development and administration of the 
Subcutaneous Administration of Bortezomib Survey (SABS), 2) development the Subcutaneous 
Administration of Bortezomib Practice Guideline, and 3) implementation of the practice 
guideline at the network of community oncology clinics.
Plan
Developing and implementing an evidence based practice guideline required 
understanding how nurses administer SC bortezomib. A descriptive web based survey was 
administered to 43 registered oncology nurses. The questions were based on an extensive review 
of the literature on administering SC injections. The information from the survey and literature 
were the basis for developing the guideline. The survey results and guidelines were reviewed 
with executives from the network for approval and implementation.
Outcomes and Results
The survey results confirmed different techniques were being used when administering 
SC bortezomib. Nurses predominantly used and preferred the abdomen for injections, 
particularly in clinics with private administration facilities. Purging versus the use of an air 
bubble was essentially divided (49% vs. 51%) within the group. There was no relationship 
between needle length and angle of insertion (p=0.34). Most nurses injected over three to five 
seconds. Nurses agreed a guideline would be important for improved patient outcomes, and 
indicated a willingness to adopt a guideline.
A SC bortezomib injection practice guideline was developed based on the survey results 
and evidence from the literature. The final guideline was presented for implementation.
Keywords: DNP capstone project; subcutaneous bortezomib; administration 
subcutaneous chemotherapy; subcutaneous injection techniques; oncology nursing.
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Capstone Project
The Subcutaneous Administration of Bortezomib Practice Guideline Capstone Project 
was conducted in partial fulfillment of the Regis University, Loretto Heights School of Nursing, 
Doctor of Nursing Practice (DNP) program. Capstone projects investigate practice issues and 
develop outcomes solutions to improve clinical practice for the benefit of a population 
(Zaccagnini & White, 2011). The identified practice issue was the lack of a standardized practice 
guideline for administering chemotherapy by the subcutaneous (SC) route. This practice 
improvement project was the development of a practice guideline for oncology nurses in a 
network of community cancer clinics. The project intended to benefit the patients with multiple 
myeloma (MM) who are receiving the chemotherapy, bortezomib, by the SC route.
Problem Recognition and Definition
Purpose
The purpose of this evidence-based practice improvement project was to develop a 
practice guideline on the SC administration of the anti-cancer chemotherapy, bortezomib. The 
intention of the guideline was to improve oncology nurses’ clinical practice in order to provide 
patient with the most relevant evidence based care for optimal outcomes. Oncology nurses who 
administered subcutaneous bortezomib (SCB) to patients at the Cancer Clinics of Excellence 
(CCE) network of community oncology clinics were asked to complete the Subcutaneous 
Administration of Bortezomib Survey (SABS) describing their SCB injection practice. Survey 
data and evidence from the clinical literature provided the basis for the practice guideline.
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Problem Statement and Change
Multiple myeloma is the second leading cause of hematologic malignancies in the United 
States (US) with an incidence rate of 22,300 and prevalence rate of 77,617 in 2010 (National 
Cancer Institute [NCI] 2013). Bortezomib was approved for the treatment of MM by the 
intravenous (IV) route in 2003. Numerous studies demonstrate that bortezomib, as a single agent 
or in combination with other agents, is highly effective in producing responses and improving 
overall survival in patients at all states of MM (Driscoll, Burris & Annunziata, 2012). The United 
States (US) Food and Drug Administration (FDA) approved the SC route of administration in 
January 2012. However, there is no published information based on clinical studies on how to 
administer SCB. There is also a lack of oncology research literature describing how to administer 
SC chemotherapy in general. The lack of evidence poses a challenge for oncology nursing 
practice. Nurses may be using different techniques for SCB injections. The clinical practice 
problem is that inconsistent injection techniques can result in patients experiencing injection site 
reactions and pain, whereas good techniques can reduce these adverse events (Girouard & 
Theoret, 2008; McEwan et al., 2010). Injection site reactions and pain can be troublesome for 
patients and may result in patients choosing to stop effective treatment (Kurtin, Knop & 
Millireon, 2012; McEwan et al. 2010).
Nursing sensitive patient outcomes (NSPO) are those patient outcomes that can be 
directly impacted by nursing interventions. The anticipated practice change associated with 
implementation of the evidence-based guideline will be consistent techniques used by all nurses 
in the CCE network when administering SCB. This practice change supports the oncology 
nursing sensitive outcomes of providing quality nursing care to minimize adverse events and 
maximize effective therapy (Given & Sherwood, 2005).
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Population, Intervention, Comparison, Outcome Practice Question
A practice question addresses the population or problem (P), the proposed intervention
(I), the comparison intervention (C) and the expected outcome of the intervention (O). Houser 
(2008) summarizes these elements as the PICO question. The clinical practice problem led to the 
following PICO question: (P) For oncology nurses in the Cancer Clinics of Excellence network 
of community clinics, (I) will the development of an standardized guideline for the 
administration of subcutaneous bortezomib (C) compared to the absence of a guideline (O) result 
in the implementation of the guideline?
Project Significance, Scope, and Rationale
The FDA approved the SC administration of bortezomib based on Phase II and Phase III 
randomized controlled trials (RCT) demonstrating equal efficacy when compared to IV 
administration. Data demonstrated the SC route reduced the incidence of peripheral neuropathy 
(PN) experienced by patient compared to the IV route (38% vs. 53%). Dose reductions due to 
adverse events were also lower in patients receiving SCB compared to IV (31% vs. 43%) 
(Moreau et al., 2011, VELCADE 2012). The implications of dose reductions and stopping 
therapy due to adverse events such as PN can include treatment failure or being changed to less 
effective therapy (McEwen et al, 2010).
Peripheral neuropathy is the most troubling adverse event associated with IV bortezomib 
and can significantly impact patient well-being. Assessing and managing PN is difficult. Results 
from an exploratory cross sectional survey of oncology nurses indicated a lack of knowledge, 
confidence, training, and proficiency in evaluating patients for chemotherapy induced PN 
(Binner, Ross & Browner, 2011). Therefore, reducing or mitigating PN by using the SC route 
can improve nursing practice and patient outcomes.
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The scope of the project was to develop a practice guideline for the administration of 
SCB and present it to CCE for implementation. In order to develop a practice guideline, the 
literature recommends surveying nurses to describe how nurses actually administer SC injections 
particularly in oncology and palliative care settings (Annerson & Willman, 2005; Kurtin, Knop 
& Milliron, 2012; Walker, Lane & McKenzie, 2010). Therefore, the SABS was administered to 
elicit how network oncology nurses were administering SCB. Educating the network nurses on 
the guideline to ensure adoption and adherence was not within the scope of the project due to 
time constraints and limiting the focus of the project.
Theoretical Foundation
The Theory of Planned Behavior. The Theory of Planned Behavior (TPB) (Ajzen, 
2012) asserts that three types of beliefs guide behavior (Figure 1):
• Behavioral beliefs, or attitudes about current behavior
• Subjective beliefs, or expectations of others about behavior
• Control beliefs, or perceived competence of and control over the behavior 
The combination of attitude about the behavior, expectations of others and competence
can lead to behavior intentions. The TPB conceptual model provided the basis for developing 
SABS questions to assess nurses’ current practice and perceptions.
The SABS was a 44-item instrument. Twenty-two competence questions (control) 
identified how nurses are currently preparing and administering SCB injections. Six 
demographic questions plus ten opinion questions (behavior) explored what nurses think about 
various aspects of SC treatments. Six perception (subjective) questions ascertained how others 
might influence SC treatment beliefs. This combination of information about nurses’ 
competence, perceptions and opinions about practice provided insights into intention to adopt a
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practice guideline (Cote, Cagnon, Houme, Abdeljelil, & Cagnon, 2012; Nirenberg, Reame, Cato, 
& Larson, 2010; O’Boyle, Henley, & Larson, 2001; Phansalker, Weir, Morris, & Warner, 2008; 
Zhou, Stoltzfus, Houldin, Marks, & Swan, 2010).
Figure 1 The Theory of Planned Behavior
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Subjective beliefs:
Perception about
practice and
expectations of
colleagues and
patients
Behavioral beliefs: Control belief:
Opinion of current competence and
practice confidence in
technique used
Behavior:Use 
of standard 
guidelines to 
administer SC 
bortezomib
Figure 1. Theory of Planned Behavior conceptual model applied to Capstone Project.
Control, behavior and subjective beliefs influence the intention to implement a practice 
guideline. Adapted from "TBP Diagram” by I. Ajzan, 2006. Retrieved from 
http://people.umass.edu/aizen/tpb.diag.html. Copyright 2006 by Icek Ajzen. Used and adapted 
with permission.
Nursing theoretical framework. Joann Duffy’s Quality Caring Model contends 
professional nursing practice is evaluated on an ongoing basis, and competency can be assessed 
through self-evaluations. The purposes of the model are to “(1) guide professional practice and
(2) provide a foundation for nursing research” (Duffy, 2010, p. 405). Nurses are responsible for 
using evidence in practice and applying attitudes and behaviors of caring. Improvements in
health outcomes are possible when caring relationships are integrated into nursing practice. 
Nurses engage in collaborative relationships with health care teams and independent 
relationships with patients and families. Patients may feel cared for when nursing practice is 
based on relationship-centered professional encounters and practice is grounded in evidence. 
Clinicians can influence patient perceptions about cancer treatment through communication of 
data in ways patients can understand and apply to their own situation (Weeks et al., 2012).
The Quality Caring Model is aligned with tenants of the advanced practice Doctor of 
Nursing role to improve health care outcomes including:
• The scientific and theoretical underpinnings for practice
• Systems and organizations
• Evidence based practice
• Interprofessional collaboration
• Research collaboration
Evidence based practice decision-making includes evidence from the literature, 
environmental and organizational context, practitioner experience, and patient preferences 
(Brown, Fielding, & Maylahn, 2009). Nurses may be relying on past experiences or other nurses 
rather than evidence for SC injection techniques (Squires, Moralejo, & LeFort, 2007). 
Addressing only the techniques of nursing skills was inadequate to design a practice guideline; 
knowledge and caring attitudes need to be integrated (Bjork & Kirkevold, 2000). The survey 
instrument evaluated practice techniques and experience through self-evaluation. The SABS 
considered interprofessional collaboration, patient preference and organizational context by 
exploring behavioral and subjective beliefs. The SABS questions were supported by the clinical
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literature. The project was in collaboration with individuals involved in research and may 
generate hypothesis for future clinical trials.
The results from the SABS and best evidence guided the development of a standard 
administration practice guideline. The expected outcome of the guideline is practice 
improvement. Multiple myeloma patients receiving SCB may experience decreased site injection 
discomfort and feel more confident in nurses’ expertise when the same techniques are being 
utilized.
Literature Selection
The primary topics for the literature search included studies on subcutaneous 
chemotherapy, SC administration techniques for any drugs and biologics, adherence to practice 
guidelines and the TPB. Literature was preferentially selected for articles from systematic 
reviews of relevant randomized controlled trials (RCTs) (Level 1 evidence), RCTs (Level II 
evidence) and well designed non-randomized controlled trials (Level III evidence). Melnyk’s 
Hierarchy of Evidence (2005) was selected because it is utilized by the Oncology Nursing 
Society (ONS).
Scope of Evidence
References related to the efficacy and safety of SC chemotherapy were primarily based 
on RCTs. Evidence for the application of the TPB was supported by case controlled and cohort 
studies (Level IV). Specific techniques were selected if there were controlled trials and case 
controlled or cohort studies. This selection resulted in focusing on site selection, needle size, 
whether to change needles before injections (dry needle), whether to purge air from the syringe 
or pull air into the syringe (air bubble or air sandwich), needle size, angle of insertion, and 
administration time. Recommendations from a review article and expert panel on administering
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SCB (Level VII) were included because there were no studies on SCB administration techniques. 
The ensuing guideline was supported with current literature which was primarily relevant to the 
administration of SC heparin, insulin, beta-interferon and azacitadine. These data were 
applicable to this project in so far as there was a dearth of studies on techniques for 
administering SC chemotherapy.
Review of Evidence
Background and the Problem
There was a lack of evidence on how to administer SC chemotherapy. Systematic reviews 
of the literature on SC administration of insulin and heparin suggested inconsistency in the 
literature to help guide nurses to utilize best evidence for injections. Literature on teaching 
patients how to self inject differed and often referenced text books rather than studies. The 
techniques supported by studies tended to have consistent findings, except for changing needles 
before injections. A common recommendation from systematic reviews, practice reviews, and 
clinical studies was the need to determine how nurses actually administer SC injections. These 
recommendations supported the need to survey the nurses for this project. The inconsistency in 
injection recommendations validated the problem of inconsistent injection techniques. 
Systematic Review of the Literature
An extensive database review was completed to identify relevant literature in the field of 
nursing, medicine, statistics, and behavior to support the project (Appendix A). Databases 
selected for review included Medline, CINAHL and Cochrane Library. Key search terms used 
included “subcutaneous bortezomib”, “subcutaneous chemotherapy”, “subcutaneous injection 
techniques”, AND “versus intravenous”, “nurs* utilization”, “procedure”, “guidelines,” 
“adherence”, “compliance”, “clinical practice skills”, “clinical decisions”, “theory of planned
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behavior”, “survey instrument statistics” and “oncology”. Inclusion criteria included 
“randomized trial”, study”, “systematic review”, “review article”, “guideline”, and “practice 
article”. Exclusion criteria included “pediatric”, “vaccine”, “editorial”, “case report”. In addition, 
a hand search of references in pertinent oncology journals was completed.
Fifty articles from clinical literature were included for this project proposal. The search 
resulted in the selection of 30 articles about SC injection techniques (Appendix A). 
Predominantly, articles on subcutaneous injection techniques were not oncology specific, and 
included two systematic reviews of literature. Additionally, five articles met the most pertinent 
criteria of “subcutaneous injection bortezomib”. There were limited articles on subcutaneous 
chemotherapy. Articles were included to support the Theory of Planned Behavior and statistical 
methods.
Subcutaneous bortezomib. Bortezomib is a proteasome inhibitor indicated for the 
treatment of all stages of multiple myeloma (Driscoll et al., 2012). The most frequent adverse 
events associated with intravenous bortezomib include peripheral neuropathy (PN). A Phase III 
randomized controlled trial (RCT) demonstrated the efficacy of SCB was non-inferior to 
intravenous bortezomib. The SC route resulted in fewer grade 3 adverse events and significantly 
less PN (38% vs. 53%, p=0.044). Fewer patients stopped treatment due to adverse events on the 
subcutaneous arm. At one-year follow up, the data for all end points of efficacy and safety 
remained similar across both arms (Arnulf et al., 2012; Moreau et al., 2011; Moreau et al. 2012). 
Pharmacokinetic and pharmacodynamics data from the Phase III RCT and a Phase I RCT 
confirmed systematic exposure was equivalent for SC versus IV administration. In both the 
Phase I and Phase III studies, SC administration sites were in the abdomen and thighs. There 
were no differences in pharmacological parameters between these sites (Moreau et al., 2012). A
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different retrospective analysis of 15 Japanese patients experiencing injection site reactions 
following SCB reported more incidences of reactions in the thigh than the abdomen (Kaminura 
et al., 2012). These data validate safe, effective administration in the abdomen and thigh. The 
literature on the Phase I and Phase III studies, and the report from Japan, do not include how the 
drug was administered subcutaneously.
Kurtin et al., (2012) described nursing strategies for administering SCB, and indicated the 
need to develop SC administration guidelines. The nursing management recommendations 
addressed site selection, use of an “air sandwich” technique (p. 408), use of a 4 -  6 mm needle, 
pinching to ensure adipose tissue and angle of needle insertion. The summary recommendations 
were based on five articles from clinical literature on subcutaneous administration of medications 
including one systematic review of literature by Annersten and Willman (2005). S. Kurtin is an 
author on two of the five references that describe the use of an air sandwich technique (Kurtin & 
Demakos, 2010; Murray et al., 2012). The source of the air sandwich technique was not 
referenced in the two articles. Use of the air sandwich technique were also recommended by the 
International Myeloma Foundation nurse leadership board at a board meeting (International 
Myeloma Foundation [IMF], 2012) The recommendations for SC administration appeared 
reasonable, however, appeared based on limited literature review and an expert panel.
Subcutaneous chemotherapy. The Oncology Nursing Society (ONS) and American 
Society of Clinical Oncology (ASC0) published standards for administering chemotherapy did 
not include guidelines on how to administer SC injections (Jacobson et al., 2011). Anti cancer 
agents and oncology supportive care agents that have been administered SC include azacitadine, 
trastuzumab, pegfilgastrim, alemtuzumab, dexamethasone, and methotrexate. Randomized 
clinical trials that compared standard IV administration to SC reported non-inferior efficacy and
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similar or decreased adverse events between the two routes. The literature reporting 
chemotherapy SC clinical trials, review articles, and clinical experiences, did not describe how 
the injections were administered (Arthur, Jubb, & Homer, 2002; Du et al., 2005; Ismael et al., 
2012; Stigenbauer et al., 2009; Walker, Lane, & McKenzie, 2010; Waters, Corrigan, Gatesman 
& Smith 2012; Wierda et al. 2011). A systematic review of Medline and CINAHL by Annerston 
& Willman (2005) found clinical trial literature on SC medications provided pharmacological, 
safety and efficacy data but no information on injections techniques or nursing 
recommendations. These findings supported this DNP student search results. The lack of 
information on how to administer SC anti-cancer agents necessitated incorporating techniques 
from other disciplines. The majority of literatures on SC injection techniques were related to 
heparin, insulin and instructing patients on self-injection.
Subcutaneous injection techniques. In a systematic review of literature on the scientific 
basis for nurses SC administration techniques, Annerston & Willman (2005) found inconsistent 
information to formulate clear recommendations based on research, and “no convincing evidence 
that a certain technique is better than another just because it has been practiced a long time” (pg. 
127). The authors stated this inconsistency prevents nurses from using best evidence for SC 
injection techniques and that additional research was needed describing how nurses are 
administering SC injections. The subcutaneous administration of bortezomib survey component 
of this project described oncology nurses practice in community outpatient clinics.
Needle size and length. Consistent data from several studies indicated appropriate needle 
gauge and length are important in SC administration. Small gauge, short needles, appropriate for 
the medication formulation, reduces the incidence of pain and injection site reactions. Skin 
thickness does not vary significantly in adults, whereas subcutaneous adipose tissue does vary in
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different anatomical sites, between genders, with increased body mass index (BMI), and waist 
circumference. In spite of adipose tissue differences, small gauge shorter needles (less than 6 
mm) have been shown to effectively deliver SC medications even in obese subjects (Akkus, 
Oguz, Uzunlulu, & Kizlgul, 2012; Arendt-Neilsen, Egekvist, & Bjerring, 2006; Birkebaek, 
Solvig, Jorgensen, Smedegaard, & Christiansen, 2008; Frid et al., 2010; Gibney, Arce, Byron & 
Hirsch, 2010;Gill & Prausnitz, 2007). However, several articles providing instructions and 
graphics on how to administer SC injections for nurses and patients recommend 25 gauge or 27 
gauge 3/8 to 5/8-inch needles (9.7 to 15mm) (Hunter, 2008; McConnell, 1990; NIH, 2012; Pope, 
2002; Rushing, 2004). Small, short needles are not appropriate for delivery of large volumes or 
for drug formulations with large particles (Gill & Prausnitz, 2007). Overall, the data suggested 
small gauge needles less than 5 mm are appropriate for even obese subjects. Short needles reduce 
the need for pinching skin at injection sites and can be injected at 90-degree angles without the 
risk of an IM injection. The use of 3/8 or 5/8-inch needles may be based on historical practices.
Dry needle and air bubble technique. Bortezomib is considered an irritant; therefore it 
is reasonable to recommend changing the needle after drawing up the medication and prior to 
injection to reduce tracking drug during the injection (Kurtin 2012). Changing the needle after 
drawing up medication has been recommended to remove particles from the vial and medication 
that may adhere to the needle, as well as reduce the risk of dulling the needle from insertion into 
a vial (Agac & Gunes, 2011; Giroud & Theoret 2008). One study of two injection techniques 
found changing the needle after drawing up the medication, use of an air bubble, and a dry 
sponge to prepare the site resulted in smaller areas of bruising (Woodridge & Jackson 1988). 
However, one randomized study and one quantitative study did not find a difference in bruising
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when needles were changed before administering the injections (Kingman, 2000; Lamblet et al., 
2011).
Frid et al., (2010) published injection recommendations for diabetic patients based on a 
systematic review of literature. The recommendations include priming, or purging, needles to 
clear dead space. Two articles providing instructions on how to administer SC injections also 
recommend purging the needle prior to injection (Hunter, 2008; NIH, 2012). In contrast to 
purging needles, Woodridge and Jackson (1988) described the use of an air bubble technique as 
one of four variables that decreased bruising with SC heparin injections, compared to purging the 
needle. A two group cross over study of 43 multiple sclerosis patients (11 control, 33 
experimental) compared standard SC beta interferon injections using a dry needle to the same 
technique using a 0.1 ml air bubble technique. The air bubble modification resulted in a 
significant (p = 0.001) decrease in site redness between the groups, as well as in the crossover 
group (p=0.002). Patients reported being more satisfied with the air bubble technique and 
continued to use it for self-injection six months after the study, suggesting a statistical and 
clinical advantage for the technique (Moore et al., 2007).
Site selection, preparation and site rotation. Appropriate sites for SC injections include 
the outer aspect of the upper arm, abdomen below the costal margins, above the iliac crest, and at 
least 5 cm away from the umbilicus, and the anterior thigh. Site rotation was recommended to 
prevent indurations and lypoatrophy (Frid et al. 2010; Girouard & Theoret, 2008; Hunter, 2008; 
Kurtin et al. 2012; NIH, 2012; Rushing, 2004). In clinical studies, bortezomib was only 
administered in the abdomen and thigh, and sites were rotated with each injection (Moreau, 
2011). Millennium Pharmaceuticals has provided a site tracker for nurses to document site 
rotations between the abdomen and thigh (velcade.com, 2013). Three articles on how to
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administer SC injections instruct on cleaning the site with alcohol prior to injections (NIH, 2012; 
McConnell1990; Rushing, 2004). However, the repeated use of alcohol may cause skin to harden 
and is not needed to cleanse the site. The World Health Organization recommends only the use 
of soap and water to prepare subcutaneous injection sites, and not alcohol (World Health 
Organization [WHO], 2010). A brief review of literature suggested use of alcohol is not 
necessary was inconclusive and conflicting (Hunter, 2008; Cocman & Murray, 2010).
Angle of insertion. There was consistency in describing the angle of insertion to ensure 
entering subcutaneous tissue rather than risking intramuscular (IM) injections based on needle 
size. A study of 388 adult diabetics demonstrated small needles, 4mm -  6 mm in length, inserted 
at a 90 degree angle without raising a skin fold will be in the SC tissue more than 98% of the 
time. Needles 6 mm to 8 mm inserted at 90 degrees will result in IM injections 5% and 15% of 
the time. A 12.7mm (1/2 inch) needle will result in IM injections 45% of the time when inserted 
at 90 degree angle and 21% of the time when inserted at 45 degree angle (Gibney, Arce, Bryon,
& Hirsch, 2010). A study of 499 subjects, including 297 healthy controls, suggested the use of 
longer needles (> 6mm) without pinching the skin or inserting at a 90-degree angle might result 
in an IM injection (Akkus et al., 2012).
Injection duration. Two quasi-experimental studies on SC injection duration 
demonstrated 30-second SC injections resulted in statistically significantly less pain and bruising 
than 10-second injections (Akpinar & Celbioglu, 2007; Zybak & Khorshid, 2007). The 
recommended dose of bortezomib is 1.3 mg/m2. To limit injection volume, the final 
concentration for SC bortezomib is 2.5mg/ml compared to 1 mg/ml for IV administration. The 
average volume for a SC injection will be just under 1 ml. (VELCADE, 2012). The
Subcutaneous Bortezomib 14
recommended infusion time for IV bortezomib is three to five seconds. There are no 
recommendations for SC injection duration (VELCADE, 2012).
Adoption of guidelines and statistics. The American Society of Clinical Oncology and 
Oncology Nursing Society (ASCO/ONS) chemotherapy handling and administration guidelines 
do not address SC administration techniques (Jacobson et al., 2011). Three descriptive survey 
studies of oncology nurses knowledge and implementation of oncology practice guidelines 
suggested approximate 80% of respondents were familiar with various clinical guidelines, 
however adoption ranged from 40% to 85% (Martin & Larsen, 2003; Nirenberg et al., 
2010;Weingart et al, 2011). Several cohort, descriptive and qualitative studies in the literature 
review supported nurses’ knowledge, competence and perceptions of clinical practice guidelines 
based on the Theory of Planned Behavior (Cote, Cagnon, Houme, Abdeljelil, & Cagnon, 2012; 
Nirenberg, Reame, Cato, & Larson, 2010; O’Boyle, Henley, & Larson, 2001; Phansalker, Weir, 
Morris, & Warner, 2008; Zhou, Stoltzfus, Houldin, Marks, & Swan, 2010).
Two articles provided guidance for content analysis of qualitative survey responses 
(Bradley, Curry, & Devers, 2007; Hsieh & Shannon, 2005). Two articles provided clarification 
on the use of Likert scales for survey instruments (Allen & Seamona, 2007; Norman, 2010). The 
authors reinforced the use of non-parametric descriptive statistics for data analysis and reporting 
Likert responses. Based on recommendations by Allen & Seamona (2007) the survey developed 
for this project forced responses and did not offer a neutral option.
Scope of Evidence
The review of literature supported the need to describe what nurses are doing in order to 
develop a guideline on administering SC bortezomib. Variables in injection technique that 
decrease injection reactions and were supported by evidence from clinical studies were explored
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and described in the survey and incorporated into the guideline (Agac & Gunes, 2011; Akkus et 
al., 2012; Akpinar & Celbioglu, 2007; Frid et al. 2010; Gibney, Arce, Bryon, & Hirsch, 2010; 
Girouard & Theoret, 2008; Hunter, 2008; Kurtin et al. 2012; Moore et al., 2007; NIH, 2012; 
Rushing, 2004; Woodridge & Jackson 1988; Zybak & Khorshid, 2007). The techniques 
included:
• Injection site selection
• Needle size and length
• Use of air bubble
• Insertion angle
• Inj ecti on durati on
Project Plan and Evaluation
Market and Risk Analysis
An overview of the market provides evidence for the value proposition of the project 
within the clinical setting and health care industry. The oncology health care market is 
competitive. Physician owned practices, such as those associated with CCE, compete with 
University and Hospital based cancer centers for patients. Competitive advantages, such as 
commitment to evidence based care, location convenience, and potentially more personalized 
care, are important differentiations (Desch & Blayney, 2006). Championing evidence-based 
nursing guidelines demonstrates the networks’ recognition of the importance of nursing for 
optimal patient outcomes.
Treatment options for patients with MM have changed. Prior to 2013, bortezomib was the 
only proteosome inhibitor on the market and has become the standard of care. A new proteosome 
inhibitor is indicated for patients who have relapsed or are refractory to bortezomib and is being
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marketed as having the advantage of less PN (Kortuem & Stewart, 2013). Clinical data 
demonstrates SCB results in reduced PN and bortezomib has proven five year survival advantage 
not demonstrated by other therapies (Velcade, 2012). Therefore, it is in the interest of patients to 
receive SCB as long as there is clinical benefit.
Project Strengths, Weaknesses, Opportunities and Threats (SWOT)
A SWOT analysis provides an overview of elements that may promote or derail a 
strategy. The analysis is generally done at the project’s strategic planning stage. The strengths 
and weaknesses are internal factors that are readily available and may be strategically addressed. 
Opportunities and threats represent external factors that need to be recognized but may not be 
controllable. A SWOT analysis was completed during the project planning and is described in 
Table 1.
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Table 1. SWOT Analysis
STRENGTHS WEAKNESS
• Congruent with DNP Capstone purpose • Limited time to implement and
• Investigated nursing practice issue complete survey
important to oncology nursing • Location of clinics across the country
• Aligned with CCE network mission to • Investigator developed survey
provide evidence based care • Competing priorities for time and
• Aligned with Millennium mission to resources
provide safe, effective treatment for • Number of nurses meeting eligibility
patient with MM criteria unknown
• Internal stakeholder collaboration • Resources to purchase software for
across functions survey
• CCE headquarters located in CO • Medical Director at Millennium lack of
support for nursing projects
THREATS OPPORTUNITIES
• IRB approval timelines • Future collaboration with CCE on
• Limited nurse participation outcomes research project
• Nurses competing time and priorities • Guideline may be considered more
• Nurses reluctant to recognize need or broadly and adapted by Millennium
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change practice
• IMF publication and congress sessions 
may influence nurse behavior
• Potential publications
• Future collaboration with IMF nurse 
leadership council to study SCB
Driving and Restraining Forces
The practice guideline project was designed to help oncology nurses provide evidence 
based care in the community setting. The project also helped demonstrate the value of nursing 
research projects to Millennium (the company) will be to ensure safe, effective use of drugs in 
actual practice settings. It was important to the mission of both organizations to provide safe, 
effective treatment and to maximize patient outcomes.
However, there were constraints associated with the project. Complying with legal, 
compliance, and regulatory guidelines associated with a product developed and marketed by the 
company resulted in numerous consults with the legal department to ensure no conflict of 
interests or revelation of proprietary information. Additionally, the project investigator was in an 
advanced practice role not associated with a clinical practice site. It was therefore necessary to 
identify community oncology clinics willing to participate in the project. One network with 
clinics in a metropolitan area in the Mountain region originally agreed to participate, and then 
declined in March, 2013. The Cancer Clinics of Excellence network (CCE) was then asked to 
and agreed to participate. The CCE headquarters in Colorado, provided convenience and access 
for the project investigator to collaborate with the Vice President of Clinical Operations and 
Manager of Research. However, the clinics associated with the CCE network are located across 
the country, limiting personal contact by the project investigator with the nurses.
Feasibility, Risks, and Unintended Consequences
It was feasible to complete the project within the academic year time frame to ensure 
completion by August, 2013 (Appendix C), in spite of CCE not being contacted until March
2013. Because the clinics are located across the United States (US), CCE was willing to adapt 
the survey instrument from a paper and pencil to web based format and to engage the clinic 
coordinators to promote the project.
Risks associated with the project included the potential lack of involvement of nurses to 
complete the survey instrument. However, in anticipation of this risk, and because the total 
number of nurses meeting the inclusion criteria were unknown, a power analysis was not done. 
The project investigator was willing to accept the number of responses received after three 
weeks. A significant risk to the company would have been the report by a nurse on the survey of 
a serious patient adverse event and the inability to identify where the event occurred. Company 
employees must report serious adverse events within 24 hours of being made aware of the 
occurrence. A risk to CCE was the potential to reveal poor practices among the nurses. However, 
the survey was reported in the aggregate, individual nurses and clinic locations could not be 
identified.
Project Team
The project team was lead by the DNP student project investigator, and stakeholders at 
Millennium and CCE. Team members at the company included the Associate Director of Health 
Economics and Outcomes Research (HEOR), one global medical affairs (GMA) Associate 
Medical Director, and the Senior Director of Scientific Alliances and Research who is a 
doctorally prepared Registered Nurse (RN) with expertise in qualitative research. Two 
statisticians agreed to run the data from the survey and the Associate Director of GMA 
Publications joined the team after the survey data were known. The CCE team members were the 
Vice President of Clinical Operations and the Manager of Research.
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Cost / Benefit Analysis
The direct and indirect costs related to the project were estimated at $23,000 (Appendix 
D). Benefits realized from a SC administration guideline include improved nurse patient 
relationships due to consistency of techniques used and nurses influence on patient perceptions 
about treatment expectations (Schwappach et al., 2010; Weeks et al. 2012). When the SCB 
evidence based guideline is adopted by CCE, patient benefit may include decreased injection site 
reactions and pain resulting in a willingness to stay on effective treatment with fewer side 
effects. The benefit to the company is an understanding of nursing practice in a community 
setting that may inform future clinical trial designs. The benefits to clinical practice and patient 
outcomes outweigh the cost associated with the project.
Project Objectives
Mission / Vision
The mission and vision of this practice improvement project linked nursing intervention 
and patient outcomes and was aligned with the Oncology Nursing Society focus on improving 
nurse sensitive patient outcomes (Given & Sherwood, 2005). The mission was to ensure safe, 
effective treatment for patients with multiple myeloma who are receiving bortezomib treatment 
through development of an administration guideline based on best evidence, clinician experience 
and patient preference. The vision was to demonstrate that CCE oncology nurses effectively 
deliver high-quality care that impacts nurse sensitive patient outcomes.
Goals / Outcomes
The goal of the project was to describe how oncology nurses at CCE actually administer 
SCB and use the best available evidence from the clinical literature to support developing the 
guideline. The expected project outcomes included implementation of the guideline at clinics in
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the CCE network. Implementation of the guideline can specifically influence nurse sensitive 
outcomes of patients with MM. Outcomes aligned with advanced practice nursing reflect clinical 
practice effectiveness (Gawlinski & McCloy, 2009). Oncology nursing patient outcomes aligned 
with good SC injection techniques includes:
Table 2 Oncology Nursing Sensitive Patient Outcomes and Measures
OUTCOME MEASURE
Symptom control and management
Functional Status
Economics
Lower incidence of peripheral 
neuropathy
Reduced injection site reactions and 
pain
Completion of effective treatment 
length of therapy
Reduced clinic time
Reduced cost
Cost effective treatment compared to 
other treatment options
Evaluation Plan
Logic Model
Logic models provide a systematic overview of a project in order to demonstrate the 
relationship between resources, activities and outcomes expected in the short and long term 
(Zaccagnini & White, 2011) Appendix B describes the logic model for this project.
Population
The target population was registered nurses in the CCE network who administered SCB. 
All nurses who had ever administered SCB were eligible to participate. There are over 200
nurses associated with the network, however the numbers who have administered SCB was not 
known. Physician assistants who were not nurses, non-registered nurses, and those who 
administered IV but not SC bortezomib were excluded from participation. The target population 
for the guideline review and implementation was the Vice President of Clinical Operation who 
will present the guideline to the network clinics.
Setting
Cancer Clinics of Excellence is a network of physician owned community oncology 
clinics in cities through the US. The network’s goal is to “Develop, influence, measure and 
support evidence-based best practice cancer care to patients in their own community” (Cancer 
Centers of Excellence [CCE], para. 1). The nurses completed the electronic survey on the 
network intra-net during clinic hours.
Design and Measurement
This practice improvement project incorporated a project investigator developed 
descriptive survey and literature review as evidence for developing the practice guideline. The 
Vice President of Clinical Operations and the Manager of Research at CCE were presented with 
the project proposal in March, 2013 and agreed to participate. The CCE electronic data base 
confirmed SCB was being administered at CCE clinics.
The Manager of Research contacted the local clinic coordinators, who have 
administrative positions and were not in supervisory roles to inform them of the project during 
conference calls. The project purpose, confidentiality, and investigator contact information were 
clarified with the coordinators. The clinic coordinators invited the nurses to participate in the 
survey and provided the link to the web survey. The survey was opened on May 20, 2013 and
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remained open for 3 weeks. The project investigator conducted weekly phone calls to remind the 
Manager of Research of the project.
The survey was administered once during a three week time period. The project 
investigator accessed the aggregated survey results at the end of the open period and analyzed all 
responses. The Excel spreadsheet with aggregated results was sent to statisticians at the 
company. The qualitative survey responses were logged by the project investigator onto a 
separate spreadsheet for analysis. Forty three (43) nurses completed the survey, all survey 
questions were answered, and there were no missing data.
The survey results were categorized for the target administration techniques and 
compared to the information from the literature. The subjective responses were analyzed for 
themes using content analysis to identify potential rationale for responses. The domains of 
beliefs from the TPB were cross referenced to evaluate behavior intentions. Where there was less 
than 50% agreement on any administration technique, or where there was more than 60% 
agreement contrary to the best evidence, questions were flagged as potential techniques that 
would require summarizing the evidence to justify changing behavior.
The survey results and a draft guideline were discussed with the Vice President of 
Clinical Operations at CCE to ensure commitment to continuing the project. It was determined 
that the results were appropriate, and the draft guideline was within the scope of CCE nursing 
practice. The final guideline will be presented by the Vice President of Clinical Operations to the 
CCE network for implementation at the national meeting of clinicians in September, 2013. 
Protection of Human Rights
Institutional Board Approval (IRB) for the project was obtained from New England IRB 
and Regis University IRB. The project investigator completed the Collaborative Institutional
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Training Initiative (CITI) certification prior to beginning the project (Appendix F). The CCE 
manager of research explained the survey purpose and process to office coordinators at the 
clinics where SCB had been administered. The coordinators, in addition to the Manager of 
Research, invited oncology nurses to consider participation and explained the purpose and 
expected outcome of the survey.
The electronic survey included an introduction explaining the survey and how to contact 
the project investigator and academic supervisor (Appendix E). Participation was voluntary as 
described on the survey introduction. The introduction emphasized that participation or non­
participation would not reflect performance expectations at the clinic. Completion of the survey 
constituted the nurses consent to participate.
The web-based survey was confidential and anonymous and the results could not be 
assigned to an individual or clinic. The project investigator was given the secure link to the 
survey. The aggregated data and spreadsheets are to be maintained in a locked office drawer for 
three years by the project investigator in hard copy form.
Instrument Reliability / Validity and Intended Statistics
The project investigator-developed survey, the Subcutaneous Administration of 
Bortezomib Survey (SABS) was adapted with permission (A. Niremberg, personal 
communication, December 11, 2012, Appendix H), from the Neutropenia Oncology Nurses 
Survey ™ (NONS). The NONS instrument was researcher developed to measure the constructs 
of the TPB and demonstrated an overall internal consistency, Cronbach alpha = 0.84. (Nirenberg 
et al., 2010, p. 767). The Subcutaneous Administration of Bortezomib Survey (SABS) 
(Appendix E) content validity was established by five oncology nurses (2 Doctor of Philosophy 
(PhD), 1 Nursing Doctorate (ND), 2 Masters of Science in Nursing Advanced Practice
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Registered Nurses (MSN, APRN), one medical oncologist, legal counsel, and three health 
economic outcomes research experts. No reliability has been established for the SABS. The 
SABS was a 44 item questionnaire, consisting of six demographic questions, 20 questions 
addressing practice to identify areas of knowledge and competence; 10 questions addressing 
opinions about SC bortezomib to identify behavioral beliefs and eight questions to identify 
perceptions of colleague’s beliefs. The survey attributes included four point Likert scales, yes 
and no and multiple-choice questions. The Likert scales forced a response in ranking. Many 
questions asked for brief explanations for the chosen response.
There were threats to the reliability and validity of the instrument including an author 
developed, single use survey instrument. In addition, responses may have been influence by 
nurses potentially being more aware of their techniques because of the survey and responded 
with what they believed the right answer should be rather than what they actually did in practice.
Non-parametric descriptive statistics, including frequency and percentages were used to 
describe the survey results. The project investigator was interested in evaluating the relationship 
between question responses such as needle length and angle of insertion, facility privacy, 
injection site preference, and consistency of techniques for nurses who believed that practice 
guideline were already in place. In these instances Fishers exact test was applied to identify 
relationships between these questions. Traditional content analysis was used to summarize the 
themes of short answer responses.
The survey described the most prevalent injection techniques used by the nurses for 
selecting injection sites, changing needles prior to injecting, selecting needle size, purging or 
including air in the syringe, and length of time administering an injection. The common themes 
obtained from the content analysis suggested the nurses rational for some administration
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practices (Bradley et al., 2007). This information and the clinical literature were used to develop 
a standardized guideline.
Project Findings and Results
The objectives of the project were to 1) develop and administer a survey of oncology 
nurses who had administered SCB in the CCE network, 2) develop a practice guideline on the 
administration of SCB, and 3) implement the guideline at CCE.
Objective One: The Subcutaneous Administration of Bortezomib Survey Results
Demographics. All respondents were female, approximately half held Bachelor of 
Science in Nursing (BSN) as their highest nursing degree, 35% held Associates Degree in 
Nursing (ADN) and 12% Diplomas in Nursing. Half were certified by the Oncology Nursing 
Society (ONS) as Oncology Certified Nurses (OCN), 30% had been in oncology nursing 
between 11-20 years. Table 3 summarizes the demographics. Table 4 validates the inclusion 
criteria, representing the number of patients per month to whom respondents administered SCB.
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Table 3 Demographics of Oncology Nurses
Highest Nursing Degree Percent Number
ADN 35% 15
BSN 51% 22
MSN 2% 1
Other (Diploma) 12% 5
Specialty Certification Percent* Number
Not certified 40% 17
OCN 51% 22
Other Certification 12% 5
^M ay not add to 100% due to rounding and multiple certifications
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Table 4 To how many patients do you administer SCB in a month?
Number of patients Percent Number
1 -  5 
6-10
More than 10
46%
33%
21%
20
14
9
Physicians were primarily responsible for ordering bortezomib by the SC route; however, 
53% of respondents indicated Nurse Practitioners (NPs) ordered the SC route in their setting.
The majority of nurses (61%) believed they were able to provide some input into decisions 
regarding the route of administration.
Administration Techniques -  Control Beliefs
Control beliefs reflect the nurse’s confidence and competence in performing the 
procedure.
Anatomical site selection. Appropriate site for SC injections include the arm, abdomen 
and thigh (National Institutes of Health [NIH], n.d.). In Phase III clinical trials, SCB was only 
administered in the abdomen and thigh (Moreau et al., 2011). Nurses reported administering 
SCB in the abdomen, arm, and thigh (Table 5). However, 88% indicated their preference is to 
administer in the abdomen (Table 6). The reasons for preferring the abdomen included more 
adipose tissue, less irritation, easy access, patient preference, and information from the package 
insert and literature. Figure 2 compares sites used for administration to those preferred. All 
respondents documented the site of injections, although only 23% reported having an anatomical 
map in the patient chart to guide site rotations for each injection.
Table 5 What anatomical site(s) do you use to administer SCB?
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Anatomical Site Yes No
Abdomen 98% 2%
Thigh 19% 81%
Arm 54% 46%
Table 6 What anatomical site(s) do you prefer to use for SCB?
Anatomical Site Yes
Abdomen 88%
Thigh 0%
Arm 12%
Figure 2 Comparison of site administration versus site preferences
Figure 2. Comparison of nurse’s actual site selections and site preferences for 
administering SCB injections. The abdomen and arm are used most often and preferred.
Facility lay out for chemotherapy administration in community clinics can vary from 
private to semi-private. There was an association between administration site preference and 
facility layout. Nurses in facilities with more private surroundings preferred the abdominal site 
for injections, while those with semi or non-private layouts preferred the arm (p=0.02).
Needle size and angle of inserting needle. Small gauge, short needles cause less 
bruising and injection reactions (Arendt-Neilsen et al., 2006; Birkebaek et al., 2008; Frid et al., 
2010; Gibney et al., 2010). Approximately 40% of the respondents indicated using 25 gauge 5/8- 
inch (15.8 mm) needles, and 56% indicated use of smaller 27 -  30 gauge shorter than 1/ 2-inch 
needle (12.7 mm). Of the nurses using the larger 25 gauge 5/8-inch needles, 61% used 45-degree 
angle for insertion and 39% used 90-degree angles. For the nurses using the smaller, shorter 
needles, 42% used 45-degree angle insertions, while 58% used 90-degree angle insertions 
(Figure 3). There was no association between needle size and angle of insertion (p= 0.35). The 
literature suggests use of 45-degree angle for needles longer than 6 mm to avoid intramuscular 
injections, and 90 degree for shorter needles (Akkus et al., 2012).
Figure 3 Association between needle length and angle of needle insertion for injections
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Figure 3. Association between needle size and angle of insertion indicates more than 
30% of nurses used 90 degree angles with longer needles. This may result in IM 
injections.
Changing needles and purging or adding air. There is rationale for changing needles 
prior to injections, also known as using a dry needle, with drugs that are irritants, such as 
bortezomib. Studies have demonstrated no reduction in bruising using a dry needle, while other 
studies have revealed reduction in bruising injections (Agac & Gunes, 2011; Kingman, 2000; 
Lamblet et al. 2011). Use of a dry needle was most prevalent, with 93% indicating they do 
change needles prior to administering SCB.
The literature frequently recommends purging air from the needle prior to injections. 
However, clinical studies have demonstrated the use of an air bubble, or air sandwich, 
significantly reduced bruising, injection pain, and increased patient acceptance (Moore et al., 
2007; Wooldridge & Jackson, 1988). The survey indicated practices were essentially split, with 
49% purging air and 51% pulling air into the syringe. Qualitative responses providing rationale 
for the techniques suggested the primary reason for purging air was having been taught to do so, 
or habit. The main reasons for using the air bubble was having had attended an in-service or 
lecture at a meeting where the technique was explained.
Administration time. Studies have demonstrated that injection times of 30 seconds 
result in less bruising than 10 second injections. Recommendations for the time to administer a 
SC injection are approximately 10 seconds per milliliter (ml) of drug (Akpinar & Celebioglu, 
2008; Chan, 2001;IMF 2012; Kurtin, Knop & Milliron 2012; Moore et al. 2007; Wooldridge & 
Jackson, 1988; Zabak & Khorshid 2007). Intravenous bortezomib is administered as a three to 
five second push (Velcade 2012). There is no information on how long to administer SCB 
injections. Approximately half of the nurses (49%) indicated administering each ml of SCB over 
three to five seconds.
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Source of practice standards. Half of the respondents believed the network had a 
standard guideline already in place for administering SCB. However, for those who indicated a 
guideline was in place, there was no consistency in injection time (p=0.19), use of air bubble 
(p=0.31), or needle length and injection angle (p=0.56). Because the literature and textbooks do 
not provide clear guidance on SC administration and there is no information in the literature on 
administering SCB, the participants were asked to identify the source of their knowledge on SCB 
administration (Table 7). Half of respondents indicated their techniques were based on in­
services. Five respondents specifically indicated the manufacturer’s sales representatives or 
nurse educator provided the in-service information, and one referenced the drug package insert 
as the source for information.
Table 7 The technique you use to inject SCB is based on:
Source______________________Yes________________________ No_______________________
My clinical experience 93% 7%
Clinical practice guidelines 72% 28%
Demonstration from 61% 39%
Summary of administration techniques, control beliefs. There were differences and 
similarities in injection techniques used for SCB among nurses. The techniques with the greatest 
consistency (> 60%) of practice included:
• Documenting site of inj ection (100%)
• Rotating injection site within the same anatomical area (67%)
• Not having an anatomical map in the chart for site rotation (77%)
• Using alcohol preparation at site (93%)
• Changing the needle on the syringe (93%)
colleagues
Inservice or education seminar 54% 46%
84%Other 16%
• Pinching a skin fold (81%)
• Administering in the abdomen (88%)
• Not administering in the thigh (81%)
• Injecting in under 10 seconds (84%)
• Not applying pressure to injection site (63%)
In general, for the techniques that varied, the technique differences were about half and half.
• Size of needle 25 gauge 5/8 inch vs. 27-30 gauge ^  inch or smaller (42% vs.
56%)
• Angle of injection 45 degree vs. 90 degree (51% vs. 49%)
• Purge needle vs. air bubble (49% vs. 51%)
Considering nurses behavior intentions, there were three evidence based techniques in the 
practice guideline that may be problematic for nurses to adopt due to their current practice. First, 
the time for an injection should be longer than 10 seconds, and ideally injected over 30 seconds. 
Second, needles longer than 1/ 4 inch (6 mm) should be inserted at 45-degree angle to reduce the 
risk of an IM injection, even with pinching the skin. Third, the use of an air bubble prevents the 
irritating drug from tracking on the needle when inserting or withdrawing the injection, and has 
been shown in two studies to cause less bruising and increase patient compliance.
Nurses and patients strongly disliked the thigh as an injection site. Including an 
anatomical map in the charts to document abdominal injection sites used may decrease the risk 
of abdominal lypohypertophy due to inconsistent site rotation (Australian Diabetic Educators 
Association [ADEA], 2011). An anatomical map was incorporated into the practice guideline 
(Appendix H).
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Opinions about Bortezomib -  Behavior Beliefs
Convenience and patient preference. Overall, nurses believed SCB was more 
convenient (Table 8) and took less time than IV bortezomib (Table 9). Reasons for believing 
SCB to be more convenient were primarily because it was quicker to administer. Comments 
reflected on patient preference and ease for the nurses and patients. Relative to responses about 
the time to administer, nurses primarily commented on the difference in time to start an IV, 
running pre medications, and hydration and gathering the supplies for an IV. Some indicated the 
actual injection time is the same as the IV push, which is congruent with the information that 
many nurses are administering the SC injection over three to five seconds. Time conveniences 
for the patient included not having to wait for a treatment chair or IV fluids. One respondent 
believed patients to be more compliant with the SC route.
Nurses were divided as to whether privacy concerns influenced site selection. However, 
the results suggest an association between site selection and facility privacy. Several commented 
that many patients, especially women, were less willing to expose their abdomen and more 
privacy was needed and provided for abdominal injections.
The majority of nurses (86%) believed patients prefer SCB to IVB. The primary reason 
for patient preference stated was that it took less time and they did not have to get an IV stick. 
Five nurses commented that some patients have experienced injection site reactions described as 
“skin irritation, sensitivity reaction at site of administration, red welts, skin sites get quite sore 
and site reactions”. Five also commented patient preference is due to decreased neuropathy with 
SCB.
Most nurses (72%) believed patients preferred the abdomen, while 28% believed patients 
preferred the arm for SC injections. The primary reason for patient preference was less pain and
Subcutaneous Bortezomib 33
redness with abdominal injections. Other reasons for preferring the abdomen were ease of 
access, modesty, and not having to redress.
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Table 8 Overall; is the SC route more or less convenient for nurses to administer than the IV 
route?
Convenience Percent
Subcutaneous much more convenient 84%
Subcutaneous somewhat more convenient 14%
Subcutaneous somewhat less convenient 0%
Subcutaneous much less convenient 2%
Table 9 Overall; is there a difference in the time it takes to administer SCB versus IVB?
Time Percent
Much less time for SC 67%
Somewhat less time for SC 28%
Somewhat more time for SC 5%
Much more time for SC 0%
Summary of opinions and behavior beliefs
Nurses believed the SC route to be more convenient and that patients prefer SCB to IV. 
These beliefs will support Duffy’s Quality Caring Model when presenting a guideline based on 
their own practice and clinical evidence. Nurses are responsible for using evidence in practice 
and applying attitudes and behaviors of caring. Improvements in health outcomes are possible 
when caring relationships are integrated into nursing practice. The Theory of Planned Behavior 
(Azjen, 2007) suggests behavior beliefs will predict willingness to act. Rationale for the practice 
guideline will include evidence from the literature about the convenience and cost effectiveness 
of SC chemotherapy (Du et al.2005) as well as information from the SABS on nurses and 
patients beliefs about the convenience of SCB.
Perceptions of Others, Subjective Beliefs
There was general agreement that all nurses used similar techniques for administering 
SCB (Table 10). The belief in consistency was due to incorporating information from attendance 
at in-services or standardized teaching in the clinic. However, several commented that there were 
different techniques being used and being observed, patients had commented on differences and 
indicated having favorite nurses for injections, and nurses had different training or different 
experiences. Respondents agreed that consistency was important to patients for continuity of 
care, safety and to reassure the patients.
Table 10 All nurses in this clinic use the same technique to administer SCB
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Same technique____________________________ Percent
Completely agree 39%
Somewhat agree 56%
Somewhat disagree 5%
Disagree completely 0%
Adherence to practice guidelines
Participating nurses agreed that practice guidelines are important for consistency and 
quality care, and if the techniques being used differed from a practice guideline, they would be 
willing to change. Half of the respondents indicated there was a standard guideline in their clinic 
for administering SCB, 20% indicated there was not a guideline and approximately 30% were 
unsure. For those who believed there was a standard guideline, there was no consistency in the 
time to administer an injection (p=0.19), use of the air bubble (p=0.31) or angle of insertion 
(p=0.56).These findings are supported by clinical literature that indicates although guidelines 
may be in place, clinician (nurses and physicians) adherence and knowledge of the guidelines is 
inconsistent even when the clinicians agree about the importance of following guidelines (Binner 
et al., 2011; Cote et al., 2012; Martin & Larsen, 2003; Nirenberg et al., 2010; O’Boyle et al., 
2001; Squires et al., 2007).
Objective Two: Results for Evidence Based Practice -  Development of the Subcutaneous 
Administration of Bortezomib Practice Guideline
A comprehensive clinical literature review supported the lack of standard SC 
administration techniques, the need to describe how nurses are administering subcutaneous 
injections and to develop evidence based practice guidelines in order to improve patient 
outcomes by potentially reducing injection site reactions and injection site pain. Reducing the 
adverse events associated with inconsistent injection techniques may result in patients complying 
with treatment and completing effective therapy.
The Capstone Project process identified the different techniques oncology nurses in a 
network of cancer clinics used to administer SC bortezomib and lack of standard practice 
guidelines for the administration of subcutaneous chemotherapy. The practice guideline 
developed was based on evidence from the actual practice of 43 oncology nurses who 
administered SC bortezomib to patients in a network of community oncology clinics and 
supported with evidence from the clinical literature. The Subcutaneous Administration of 
Bortezomib Practice Guideline included descriptions of potential patient benefit, levels of 
evidence and graphics for specific techniques (Appendix H) Permission was granted for use of 
the graphics (Appendix G).
The specific techniques in the guideline recommendations included:
• Anatomical site rotation and use of an anatomical map
• Appropriate method of skin pinch to ensure access into adipose tissue
• Use of 45 degree angle with needles that are longer than 6 mm (1/ 4 inch) to avoid 
risk of intramuscular injections
• Use of dry needle
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• Use of air bubble
• Injection duration of 10 to 30 seconds 
Objective Three: Implementation of the Practice Guideline
The Subcutaneous Administration of Bortezomib Practice Guideline was presented to the 
Vice President of Clinical Operations for review and approval. The Vice President of Clinical 
Operations will present the guideline for implementation at the September 2013 CCE national 
meeting. The project investigator will follow up with the Vice President in October, 2013.
According to the constructs of the Theory of Planned Behavior (Azjen, 2012), 
incorporating information on what the nurses were actually doing, what they believed about SC 
bortezomib and their perceptions of what patients and colleagues believed about SC bortezomib, 
implementation of the guideline is likely to occur. Adoption of the practice guideline at CCE is 
possible with appropriate staff education.
Joan Duffy’s Quality Caring Model can be the framework for educating CCE nurses 
about the Subcutaneous Administration of Bortezomib Practice Guideline. The model contends 
that through self-evaluation of practice, collaborative relationships, and adoption of evidence- 
based practice, nurses can improve patient caring and outcomes.
Limitations, Recommendations and Implications for Practice 
Limitations
There are several limitations to this project. First, the project investigator developed the 
SABS survey instrument based on adaptation of the Neutropenia Oncology Nurse Survey™. 
Although the SABS was reviewed for content validity, there is no established and validity for 
this instrument. In addition there is no instrument reliability. Second, the survey results only 
reflect one community oncology network. Third, the number of respondents was small. Finally,
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the survey was administered after some of the surveyed nurses had attended education sessions 
on SCB injections which may have influences their responses. The findings cannot be 
generalized to other community oncology networks, independent community practices, or 
academic cancer centers.
Recommendations
The purpose of this project was to develop and implement a practice guideline on the 
administration of SCB for a community oncology network. The project was in alignment with 
the clinical literature assertions that nurses use different techniques for SC injections. Different 
techniques are recommended in the literature and textbooks. Project surveyed nurses agreed 
guidelines result in consistency of care that is important to patients. It would be reasonable to 
recommend oncology nurses assess how nurses are administering SC injections in order to better 
understand current practice.
The results of this project suggested potential opportunities for future nursing research. 
There is no evidence that adopting a practice guideline will result in fewer injections site 
reactions. The incidence of SCB injection site reactions in actual practice is unknown. A clinical 
study comparing the incidence of injection site reactions and patient reported outcomes when 
following the guideline injection technique is needed.
A weakness associated with new SC drugs is the lack of information drug manufacturers 
provide on how to administer the SC injections (Annerson & Williams, 2005). Drug 
manufacturers could improve data reports by including evidence based SC administration 
techniques in the drug study designs. Including information from clinical trials on how to safely 
administer SC injections, along with the safety and efficacy data, may mitigate the risk of 
injection site adverse events when drugs are more widely used after approval. This project
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exposed members of the Millennium project team to the importance of considering nursing 
interventions in study design to improve patient outcomes.
The manufacturer of bortezomib, Millennium, the Takeda Oncology Company, was 
willing to sponsor this project in the interest of identifying what nurses are actually doing when 
administering SC bortezomib injections. Millennium may not be able to recommend the 
guideline that was developed for this project. Cancer Clinics of Excellence reviewed the 
guideline and agreed to its implementation. A comprehensive training plan that engages 
Advanced Practice Nurse Practitioners (APRNs) as champions throughout the network may 
improve the likelihood of widespread adoption. Nurse Practitioners currently have responsibility 
for ordering SCB in some of the network clinics. Championing and promoting evidence based 
guidelines can provide APRNs continuity in advanced practice roles within the CCE 
organization. The APRNs can influence the outcomes that are most meaningful to patients by 
modeling the importance of consistent caring practice to patients and supporting professional 
collaboration with evidence based practice (Gawlinski & McCloy, 2009). Adopting the guideline 
will contribute to nursing practice by demonstrating evidence based care impacts nurse sensitive 
patient outcomes.
Summary
Essential to the Doctor of Nursing Practice (DNP) role is improving patient outcomes and 
the overall quality of healthcare organizations (Zaccagnini & White, 2011). The Subcutaneous 
Administration of Bortezomib Guideline Capstone Project endeavored to advance oncology- 
nursing practice in a network of community oncology clinics in order to improve patient 
outcomes. Additionally, the project introduced the value proposition of nursing outcomes 
projects in a global oncology pharmaceutical company medical affairs organization. The project
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addressed the first three essentials of a DNP education (American Association of Colleges of 
Nursing [AACN], 2006).
First, the scientific underpinnings of practice were met by utilizing evidence from the 
clinical literature and actual practice. Second, the project investigator demonstrated 
organizational and system leadership for quality improvement and system thinking within in a 
network of oncology clinics committed to evidence based practice and a global pharmaceutical 
company committed to developing effective oncology therapeutics. Third, clinical scholarship 
and analytical methods for evidence based practice were achieved by critically collecting and 
analyzing data to develop a guideline consistent with the principles of evidence based practice. 
The Subcutaneous Administration of Bortezomib Capstone Project met the criteria of 
investigating a practice issues and developing outcomes solutions to improve clinical practice for 
the benefit of a population.
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patients each arm to 
reach 80% power was 
reached;
Primary
Outcomes/
Measures/R
esults
20 item 
Chemotherapy 
Handling 
Questionnaire, 
mailed w stamped 
return envelope, 
validated by expert
for 5FU SC / IM or IVP 
significantly lower risk of 
hospitalization than IV 
infusions. Substantial 
geographic variations 
"important public health 
implications because if the
Met primary outcome 
non-inferiority of SC vs 
IV, efficacy, PK/PD, and 
similar toxicity profile.
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panel, stability 
Cohens kappa 0.8. 
Synthesis: compared 
demographics to 
ONS membership 
for experience, 
degree, certification, 
geographic response 
rate, FT/PT, practice 
setting, # pts/day
modes of administration are 
associated with subsequent 
outcomes it may be possible 
to take steps to prevent 
negative outcomes by 
controlling for the preferred 
mode/route of 
chemotherapy 
administration" (p 922).
Author
Conclusions
/
Implications 
of Key 
Findings
Availability of 
protective equip 
100%; use of gloves 
99%, gowns 53%, 
goggles rare; 
preparation 49% 
RPh, 40% nurses, 
Education & 
Training 87%; 
Policies and 
procedures 85%
Prevalence of 
administration: 72% IV <1 
hour or 1 - 8 hrs; 15% IV> 8 
hours; 12% IVP; 1%
SC/IM. Patients 
significantly less likely to 
be hospitalized with SC and 
infusion > 8 hrs
SC non-inferior to IV = 
valid administration 
option that "Could 
provide substantial time 
saving for patients, 
physicians and nursing 
staff'( p877)
Strengths/li
mitations
High response rate 
from experienced 
nurses. Not 
generalizable due to 
he expertise of the 
respondents may not 
reflect general 
practice
SEER data highly reliable 
and valid to monitor cancer 
control & prevention. 
Medicate covers IV 
chemotherapy inpatient and 
outpatient. Limitations: 
cannot be generalized 
beyond women >65 y/o 
with breast cancer who are 
not covered by HMOs or 
fully covered by Medicare 
A&B. Codes could be 
misclassified, dose of 
chemotherapy not known 
that may have impact on 
adverse events
RCT with PK/PD 
evidence. Limitations, 
applicable only in neo­
adjuvant setting. SC dose 
mixed with 10,000U 
RHuPH enzyme to 
improve SC absorption. 4
Funding
Source
Not indicated NCI Roche Pharmaceutical
Comments Applicable to PICO 
due to design of 
questionnaire and 
evidence that 
oncology nurses
Risk of adverse events 
lowest with SC vs IV 
administration. Only 1% of 
admin is SC, possible lack 
of knowledge due to less
Ph III non-inferiority of 
SC MOAB.
Administration technique 
not clearly described. 5 
min SC administration
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prepare own 
chemotherapy, 87% 
education on chemo 
admin, 85% policies 
in place. Suggests 
capstone population 
may be preparing 
chemo, may not 
have been educated 
and not have, or not 
realize SOP for SC 
admin
frequent mode. Substantial 
geographic variations 
"important public health 
implications because if the 
modes of administration are 
associated with subsequent 
outcomes it may be possible 
to take steps to prevent 
negative outcomes by 
controlling for the preferred 
mode/route of 
chemotherapy 
administration" (p 922). 
Application to PICO - may 
support lack of SOP for SC 
administration and 
opportunity for teaching and 
change in practice.
would be difficult to 
administer and would 
require extensive nursing 
teaching. Butterfly used 
for SC administration 
and sites were moved due 
to volume (Personal 
communication T. Caver 
October 5, 2012). 
Application to PICO 
supports literature does 
not describe how to 
administer SC anti cancer 
agents
4 5 6'
Article Title Explaining the role 
of organizational 
policies and 
procedures in 
promoting research 
utilization in 
registered nurses.
Patients’
expectations about 
effects of 
chemotherapy for 
advanced cancer
Oncology nurses’ 
use of national 
comprehensive 
cancer network 
clinical practice 
guidelines for 
chemotherapy- 
induced and febrile 
neutropenia
Author, year, 
Journal
Squires, J.E., 
Moralejo, D., 
LeFort, S.M. (2007 
June 5)
Implementation 
Science 2(17) 
doi:10.1186/1748- 
5908-2-17
Weeks, J.C., 
Catalano, P.J., 
Finkelman, M.D., 
Mack, J.W., 
Keating, N.L., 
Schrag, D. (2012 
October 25) New 
England Journal o f 
Medicine. 367(17) 
1616-1625 doi: 
10.1056/NEJMoa.1 
204-410 
Retrieved from 
nejm.org
Nirenberg, A., 
Reame, N.K., Cato, 
K.D., Larson, E.L. 
(2010 November) 
Oncology Nursing 
Forum. 37(6) 765­
772 doi:
10.1188/10.ONF.76
5-773
Data Base & Key BioMed Central, NEJM.org ONS.org/publicatio
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Words Open Access. 
Perceptions nurses 
utilization 
procedures
Patient perceptions 
chemotherapy
ns Evidence
practice, adherence,
procedures,
guidelines,
perceived
competence
Research Design Cross sectional 
survey
Descriptive survey 
interview
Cross-sectional
survey
Level of Evidence VI VI VI
Study Aim/Purpose Identify factors 
influencing 
registered nurses to 
use and follow 
organizational 
policies and 
procedures
Characterize the 
expectations of 
patients with 
advanced colorectal 
and lung cancer 
about the 
effectiveness of 
chemotherapy and 
expectations for 
cure and to identify 
the clinical, 
socioedemographic 
and health system 
factors associated 
with expectations of 
cure (p 1617)
Describe oncology 
nurses use of 
guidelines in 
practice
Methods/ Study 
Appraisal
Staff and agency 
RNS in one eastern 
Canadian Provence, 
Newfoundland and 
Labrador. Medical, 
surgical and critical 
nurses. 464 surveys 
mailed, 58% 
response rate N= 
248 .
Staff Nurse 
Questionnaire 
(SNQ) 96 items 
revised from Nurses 
Practice 
questionnaire 
(NPQ), tested for 
reliability on 12 
nurses. Descriptive 
statistics
Patients (or 
surrogate if pt too 
ill) from patients in 
national Cancer 
Care Outcomes 
Reearch And 
Surveillance 
(CanCORS) study 
with advanced 
colorectal or lung 
cancer. Interviewed 
4 -  7 months after 
diagnosis by 
telephone interview 
software. Questions 
adapted from Los 
Angeles W omen’s 
Health Study to 
elicit “how likely 
did you think..”
Neutropenia 
Oncology Nurses’ 
Survey Web based 
random sample of 
US RNs members 
of ONS. Survey 
available online for 
two weeks through 
ONSEdge. Survey 
measured constructs 
of Theory of 
planned behavior: 
subjective norms, 
attitudes, perceived 
behavioral control, 
perceived barriers 
to use of NCCN 
guidelines. 
Psychometric 
properties for
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summarized data. 
Cross tabulations 
and chi square for 
dichotomous data, 
stepwise 
multivariate 
analysis for factors 
predicting use of 
P&P
likert like responses 
of very, somewhat, 
a little, not at all 
likely or don’t 
know.
Questions on 
patient / physician 
communication, 
QoL, patient role in 
decision making . 
Four level 
responses analyzed 
with non-parametric 
test for trends.
instrument internal 
consistency, 
Cronbach alpha = 
0.84.
Descriptive 
statistics compared 
to ONS 
membership. 
Bivariate analysis 
of identified 
variables,
Primary
Outcomes/Measures
/Results
Table 2 Frequency 
of use of resources 
for practice. In the 
frequently/always 
use category: 81.9% 
P&P, 81.1% 
personal
experience; 58.5% 
fellow nurses;
32.6% Always done 
that way
1193 of 1274 
patients (93%) 
opted for
chemotherapy. 69% 
with lung cancer 
and 81% with 
colorectal believed 
chemo was very 
likely to cure their 
cancer. Variables 
associated with 
expectations were 
colorectal cancer 
and nonwhite race. 
Patients from 
integrated health 
care networks were 
less likely to 
provide inaccurate 
responses.
Guidelines were 
more likely to be 
used when expected 
by physicians and 
nurse colleagues. 
Oncology certified 
nurses perceived 
fewer barriers to 
use of guidelines
Author 
Conclusions/ 
Implications of Key 
Findings
Multivariate 
regression analysis 
identified three 
significant 
predictors of being 
a user versus non­
user of RBP 
overall: awareness, 
awareness by 
regular use, and 
persuasion. Six 
significant
Rate of inaccurate 
responses higher 
than from previous 
small studies. 
“paradoxically, 
patients who 
reported higher 
scores for physician 
communication 
were also at higher 
risk for inaccurate 
expectations”
Although 80% 
reported using 
guidelines for CIN 
and FN, only 56% 
reported it was their 
own decision. On 
line survey of ONS 
members feasible. 
Provided insights 
into future member 
surveys.
Need to develop
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predictors of being 
a consistent versus 
less consistent user 
of RBP overall 
were also identified: 
perception of P&P 
existence, unit, 
nursing experience, 
personal experience 
as a source of 
practice knowledge, 
number of existing 
research-based 
P&Ps, and lack of 
time as a barrier to 
consulting P&P 
manuals.
(p1620) Patients 
ability to make 
informed decisions 
will be impaired if 
they don’t 
understand 
treatment is not 
curative. This 
suggests a 
significant obstacle 
to end of life 
planning. 
“Physicians have 
some ability to 
influence patients’ 
understanding.
standard nursing 
protocols. Most 
respondents from 
community settings 
where oncology 
care is shifting.
Strengths/limitation
s
Multicentered 
survey with >200 
respondents.248 
respondents may 
not have been 
enough to identify 
differences in 
variables. Nurses 
alerted to existence 
of P&P being 
important. 
Questionnaire not 
validated. Not 
generalizable 
outside of Canadian 
provences or 
community practice
Very large sample 
size, population 
based and scope of 
sociodemographic 
data collected. 
Limitations: due to 
timing of interview 
after diagnosis, 
unable to comment 
on beliefs of those 
who died shortly 
after receiving 
chemotherapy. 
Single survey does 
not identify if 
beliefs changed 
over time. 
Interviewers may 
not have been 
skilled enough to 
delve more deeply 
into responses
309 oncology 
nurses providing 
direct patient care, 
self selected from 
ONS membership. 
Limitations: Only 
9% response rate. 
Web based format 
open only to 
computer users. 
Survey conducted 
one month before 
ONS Congress may 
have respondents 
with more 
professional 
interest. Self report 
may result in 
overestimation
Source of Funding Not indicated NCI Not indicated
Comments Factors influencing 
use of P&P include 
perceptions of 
whether or not 
procedure exists,
Support of PICO -  
clinicians can 
influence patient 
perceptions about 
treatment. Suggests
Based on Theory of 
Planned Behavior 
supported basis for 
survey development 
and assessing
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personal experience nurses can influence outcomes.
and peer preferences about Provides framework
experience. This SC. Supports for project survey:
information may importance of • Attitudes
support hypothesis clinician • Subjective
that whether or not communication of norms:
SC procedure in actual data in ways perceptions
place, nurses may patient can about
rely on past understand and colleagues
experience or other apply to own • Perceived
nurses for SC situation. self
chemo competence
administration. • Perceived 
barriers
• Reported 
use
7 8 9
Article Title Updated survival 
analysis of a 
randomized phase 
III study of 
subcutaneous 
versus intravenous 
bortezomib in 
patients with 
relapsed multiple 
myeloma
US cancer center 
implementation of 
ASCO/Oncology 
Nursing Society 
chemotherapy 
administration 
safety standards
From simplicity to 
complexity: 
developing a model 
of practical skill 
performance in 
nursing
Author, year, 
Journal
Arnulf, B., 
Pylpenko, H., 
Groscki, S., 
Karamanesht, L., 
Lelu, X., Van de 
Velde,
H.,...Moreau, P. 
(2012, June 11).
Weingart, S,N, Li, 
J.W., Zhu, J., 
Morway, L., Stuver, 
S.O., Shulman,
L.N., & Hassett 
M.J. (2011 Dec 6) 
Journal of 
Oncology Practice. 
Retrieved from 
joppubs.org as 
doi :10.1200/J OP.20 
11.000379
Bjork, I T., 
Kirkevold, M., 
(2000) Journal of 
Clinical Nursing. 
9. 620-631
Data Base & Key 
Words
MedLine
Subcutaneous
bortezomib
ASCO Publications
Adherence
guidelines,
chemotherapy
administration
CINHAL 
Clinical nursing 
skill, practice skill, 
skill performance
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Research Design Written survey observational
Level of Evidence II VI VI
Study Aim/Purpose Update data from 
Phase III non­
inferiority study
Determine the 
implementation of 
chemotherapy 
administration 
standards in NCI 
designated cancer 
centers
New model of 
nursing practical 
skill performance
Methods/ Study 
Appraisal
Phase III RCT
Non-inferiority
design
Updated time to 
event endpoints 
Response rates and 
adverse events 
Comparing IV and 
SC administration 
2:1 randomization
Written survey 
using exact, or near 
exact phrasing of 
standards. Degree 
of implementation 
responses on 4 scale 
likert or binary 
yes/no scale. 
Defined standard as 
fully implemented 
if more than 90% of 
responses were 
mostly positive, 
partially
implemented if 50­
90% mostly 
positive and not 
implemented if 
<50% positive. 
Internal consistency 
within domains 
Cronbachs alpha 
>0.7 for six of 8 
domains. 44 of 55 
eligible centers 
responded.
Videotaping 4 new 
nurses 3 times over 
3-5 months during 
skills of wound 
dressing change and 
post=-op
ambulation. Nurses 
and patients were 
interviewed. Nurses 
on intentions and 
appraisals before 
and after and 
patients on 
expectations and 
experiences.
Models of skills 
were created with 
coding scheme for 
action and set of 
performance 
categories 
developed: 
substance and 
sequence, accuracy, 
fluency, integration 
and caring conduct. 
Empirical data were 
compared with the 
components to 
check model 
validity
Primary
Outcomes/Measures
/Results
Best response after 
10 cycles 
bortezomib + 
dexamethasone 
IV vs. SC 
52% each arm
6 standards were 
fully implemented 
in at least 80% of 
the centers. The 
standards with 
lowest
Practical skills are 
highly complex and 
what seems like 
simple skills are 
integrated and 
comprehensive.
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23% / 22% CR 
9.7 mo /9.6mo TTP 
9.3 mo/8.6 mo PFS 
76% /78% 1 yr OS
PN
53% / 38%
subsequent therapy 
57% / 53%
implementation 
were providing 
chemo education 
materials before 
administering 
chemo, providing 
oral chemo-specific 
materials, written 
guidance about 
regime specific lab 
testing intervals and 
chart
documentation 
during chemo 
planning. Only 4 
centers had fully 
implemented all 31 
standards
Author 
Conclusions/ 
Implications of Key 
Findings
Confirms SC as 
effective as IV with 
improved safety 
profile
Slow adoption may 
be due to 
complexity of 
standards and the 
infrastructure 
required to support. 
Even if electronic 
systems were to 
become available 
through HER, it 
would require 
significant work 
flow changes and 
staffing. Lack of 
detailed written 
patient education 
and support may 
“account for the 
problems with safe 
handling, adherence 
and reporting 
noted” in recent 
literature.
Variability in NCI 
center practice 
suggests even more 
variability in other 
settings.
Relying on 
procedure 
knowledge is 
inadequate because 
technical skills are 
complex actions. 
Cannot just address 
motor component of 
skills, must 
integrate knowledge 
and caring 
considerations
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There is variability 
in adherence to the 
safety standards, 
with opportunities 
for improvement.
Strengths/limitation
s
Observational study 
may altered natural 
practice. Observer 
bias.
“Social desirability 
bias may have led 
respondents to 
report more 
favorable adherence 
“(p 5). Centers are 
complex and 
multiple specialties 
are involved in 
chemotherapy 
process, though one 
person facilitated 
the survey, usually 
the clinical 
pharmacist. 
Nonresponse bias 
from the 11 centers 
that did not respond 
may differ.
Small study, 
theoretical nature 
designed to develop 
a model.
Source of Funding Packaging concepts 
Assoc. LLC
Authors Weingart, 
S.N & Shulman, 
L.N
Not indicated
Comments Nurses adherence to 
practice guidelines 
may not be 
congruent with 
perceptions of 
practice. Support 
PICO hypothesis of 
perceptions versus 
practice of SC 
administration
Supports project 
hypothesis of 
variable adherence 
to standard 
procedures even 
when standards 
exist.
Cannot assume 
because a procedure 
is in place nurses 
are able to perform 
what may seem to 
be simple nursing 
skills. Nursing 
education focus on 
theory and 
professionalism has 
resulted in less time 
on clinical skills.
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Article Title Revisions to the 
2009 ASCO/ONS 
standards for safe 
chemotherapy 
administration: 
expanding the scope 
to include inpatient 
settings
Pharmakokinetics, 
pharmacodynamics 
and covariate 
analysis of 
subcutaneous 
versus intravenous 
administration of 
bortezomib in 
patients with 
relapsed multiple 
myeloma.
Chemotherapy- 
induced peripheral 
neuropathy: 
assessment of 
oncology nurses' 
knowledge and 
practice.
Author, year, 
Journal
Jacobson, J.O., 
Polovich, M., 
Gilmore, T.R., 
Schulmeister, L., 
Esper, P., LeFebvre, 
f  B., & Neuss, M.N. 
(2011) Journal o f 
Oncology Practice . 
Retrieved from 
http://jop.ascopubs. 
org/ content/ 8/1/2.fu 
ll?sid=9c7e1e88- 
b12a-4cc1-8641- 
e78ba3e5b3e2
Moreau, P., 
Karamanesht, I.I., 
Dominkova, N., 
Kyselyova, M., 
Vilchevska, K.V., 
Doronin, V.A., 
Schmidt, A., 
...Facon, T. (2012 
Sept 25) Published 
online Clin 
Pharmacokinet. 
DOI
10.1007/s40262-
012-0010-0
Binner, M., Ross, 
D., Browner, I. 
(2011 July) 
Oncology Nursing 
Forum 38(4)448- 
454
doi:10.1188/11.ON
F.448-454
Data Base & Key 
Words
ASCO publications
Chemotherapy
standards
Medline
subcutaneous
bortezomib,
pharmacokinetics
ONS.org oncology 
nurs* knowledge, 
practice, perception
Research Design Practice guideline Phase III open label 
RCT AND 
Randomized Ph 1
cross sectional, 
descriptive
Level of Evidence VII II VI
Study Aim/Purpose Revision of 
standards for safe 
chemotherapy 
administration
present a 
comprehensive 
analysis of the 
pharmacokinetics 
and
pharmacodynamics 
of subcutaneous 
versus intravenous 
bortezomib, and to 
evaluate the impact 
of the subcutaneous 
administration site,
explore oncology 
nurses knowledge 
and practice 
behavior of 
assessing for 
chemotherapy 
induced PN
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subcutaneous
injection
concentration and 
demographic 
characteristics on 
bortezo- mib 
pharmacokinetics 
and
pharmacodynamics.
Methods/ Study 
Appraisal
40 stakeholders, 
including medical 
oncologists, 
oncology nurses, 
oncology
pharmacists, social 
workers, practice 
administrators, and 
patient advocates, 
as well as 
representatives 
from American 
Cancer Society, 
Association of 
Community Cancer 
Centers, National 
Quality Forum, 
National Coalition 
for Cancer 
Survivorship, The 
Joint Commission, 
and Institute for 
Safe Medication 
Practices met for a 
single day and, 
using a structured 
process, drafted 64 
chemotherapy 
administration 
safety standards. 
The draft standards 
were subsequently 
presented to the full 
group of 
participants for 
comment and 
discussion, and
age >18 <65 
relapsed or 
refractory MM 1 - 3 
prior therapies. In 
Ph III 32 of 222 
patients had PK/PD 
(18 SC & 14 
IV)from Ph I 10 
patients each group. 
Power ratio and 
90% CI point 
estimates AUC 
mean. Equivalence 
defined as 90% CI 
falling between 85­
125%. Regression 
covariates 
demographics 
PK /PD collected 
day 11 of cycle 1 
immediately or 30 
minutes pre-dose 
and 2, 5, 15 and 30 
minutes post dose, 
and 1, 2, 4, 6, 10,
24, 36 and 72 hours 
post dose 
comparing SC vs 
IV PK/PD. 
Pharmacokinetic 
parameters included 
the area under the 
plasma
concentration-time 
curve (AUC) from 
time zero to the last 
quantifiable time-
convenience sample 
39 oncology nurses 
in two hospital 
based outpatient 
chemotherapy 
infusion clinics 
Author developed 
questionnaire "The 
Chemotherapy 
Induced Peripheral 
Neuropathy: 
Assessment o f 
Oncology Nurses 
Knowledge and 
Practice
Questionnaire" 16 
knowledge and 16 
practice items, 9 
demographic items. 
Content validity 
0.95 and reliability 
Cornbach alpha 
0.85. Descrriptive 
statistics
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assessed for 
redundancy and 
gaps. Participants 
voted on the draft 
standards within 1 
week of the 
workshop, and the 
SG used the voting 
results to clarify 
and edit the 
standards, reducing 
their number to
35.(p
point (AUClast), 
maximum (peak) 
plasma drug 
concentration 
(Cmax), and time to 
Cmax (tmax). 
Pharmacodynamic 
parameters were 
calculated by 
analysis of data on 
the percentage 
inhibition of the 
20S proteasome in 
blood over time, 
which was 
determined based 
on the change in 
pro- teasome 
activity from 
baseline (pre-dose) 
to subsequent time 
points.
Pharmacodynamic 
parameters included 
area under the 
effect-time curve 
from time zero to 
72 h (AUEC72), 
maximum 
percentage 20S 
proteasome inhibi­
tion [maximum 
effect (Emax)] and 
time to Emax.
Primary
Outcomes/Measures
/Results
Primary change was 
to include inpatient 
setting
Table 1. systemic 
exposure was 
equivalent to 
subcutaneous 
versus intravenous 
administration, 
mean AUClast was 
155 versus 151 
ngDh/mL, subcuta­
neous injection 
concentration had
75% rated 
assessment skills as 
poor or fair, only 
15% had prior PN 
assessment 
teaching, barriers 
included lack of 
knowledge, time 
and inadequate 
tools, 33% routinely 
screened for PN
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no appreciable 
effect on 
pharmacokinetic 
parameters, blood 
20S proteasome 
inhibition were also 
similar with 
subcutaneous 
versus intravenous 
bortezomib. the site 
at which the 
subcutaneous 
injection was 
administered and 
the concentration o f 
the injected solution 
(2.5 or 1 mg/mL) 
did not appear to 
affect the 
pharmacokinetic 
and
pharmacodynamics
parameters o f
bortezomib
following
subcutaneous
injection,
demonstrat- ing the 
feasibility o f  using 
a higher 
subcutaneous 
injection
concentration (2.5 
mg/mL) in order to 
minimize the vol­
ume injected per 
dose o f bortezomib. 
In both studies, 
subcutaneous 
injection sites were 
the thighs and the 
abdomen (but not 
the arms); the 
absence o f any 
apparent differences 
in pharmacological
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parameters between 
these sites indicates 
that both represent 
equally feasible 
sites for the 
subcutaneous 
administration o f 
bortezomib. 
Addition- ally, 
demographic 
covariates did not 
appear to have an 
impact on the 
systemic exposure 
with subcutaneous 
bort- ezomib, when 
dosed on the basis 
of BSA, suggesting 
the feasibility o f 
this route o f 
administration 
regardless o f  a 
patient’s age or 
bodyweight.
Author 
Conclusions/ 
Implications o f  Key 
Findings
Standards, 12, 13,
14 Drug prep.
12. A second person 
(a practitioner or 
other personnel 
approved by the 
practice/institution 
to prepare or 
administer 
chemotherapy) 
independently 
verifies each order 
for chemotherapy 
before preparation, 
including 
confirming:
A. Two patient 
identifiers
B. Drug names
SC administration 
non inferior to IV. 
Efficacy related to 
systemic exposure, 
not Cmax. SC 
resulted in less 
grade 3 adverse 
events, most 
importantly, 
significantly less 
Peripheral 
Neuropathy
Lack o f confidence, 
knowledge and 
assessment skills 
prevent routine 
assessment. Need 
for clinical 
guidelines on PN 
assessment and 
more assessment 
education
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C. Drug dose
D. Drug
volume
E. Rate of
administrati
on
F. Route of
administrati
on
G. The
calculation
for dosing
(including
the variables
used in this
calculation)
H. Treatment
cycle and
day of cycle
13. Chemotherapy 
drugs are labeled 
immediately upon 
preparation, 
including, at 
minimum:
A. Patient’s full 
name and a 
second 
patient 
identifier 
(e.g., 
medical 
record 
number, 
DOB)
B. Full generic 
drug name
C. Drug 
administrati 
on route
D. Total dose 
to be given
E. Total 
volume
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required to 
administer 
this dosage
F. Date o f 
administrati 
on
G. Date and 
time o f 
preparation
H. Date and 
time o f 
expiration 
when not for 
immediate 
use*
*Immediate use 
must be defined by 
institutional policy, 
state, and federal 
regulations (e.g. use 
within 2 hours).
Practices/institution 
s are not expected 
to be in full 
compliance with 
this standard i f  they 
currently have 
electronic systems 
that are unable to 
meet these labeling 
requirements. 
Appropriate 
changes should be 
implemented as 
soon as possible to 
ensure that 
electronic labels 
integrate all o f  these 
elements.
14.
Practices/institution 
s that administer 
intrathecal
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medication 
maintain policies 
specifying that 
intrathecal 
medication will:
A. Not be 
prepared 
during 
preparation 
of any other 
agents.
B. Be stored, 
once
prepared, in
an isolated
container or
location
with a
uniquely
identifiable
intrathecal
medication
label.
C. Be delivered 
to the
patient only 
with other 
medication 
intended for 
administrati 
on into the 
CNS.
Standard 18-20 
Administration
18. Before
chemotherapy
administration:
Confirm with the 
patient his/her 
planned treatment 
prior to each cycle;
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At least two 
practitioners or 
personnel approved 
by the
practice/institution 
to prepare or 
administer 
chemotherapy, 
verify the accuracy 
of:
A. Drug name
B. Drug dose
C. Drug 
volume
D. Rate of 
administrati 
on
E. Route of 
administrati 
on
F. Expiration 
dates/times; 
if
applicable: 
[expiration 
date/time is 
not required 
if for
immediate
use*]
G. Appearance 
and physical 
integrity of 
the drugs
H. Document 
to indicate 
verification 
was done 
and;
I. At least two 
individuals, 
in the
presence of 
patient, 
______ verify the
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patient
identificatio
n using at
least two
identifiers
(e.g.,
medical
record
number,
DOB)
* Immediate use 
must be defined by 
institutional policy, 
state, and federal 
regulations (e.g. use 
within 2 hours).
19. Extravasation 
management 
procedures are 
defined and align 
with current 
literature and 
guidelines; antidote 
order sets and 
antidotes are 
accessible.
20. A licensed 
independent 
practitioner is on 
site and 
immediately 
available during all 
chemotherapy 
administration.
***In organizations 
or home care 
settings where 
chemotherapy may 
be administered 
24/7,
patients/caregivers 
should be explicitly
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educated in 
procedures for 
unplanned events 
and circumstances.
Strengths/limitation
s
PK/PD data from 
two randomized 
studies confirms 
non inferiority of 
SC vs IV 
administration. 
Small number of 
patients with grade 
3 adverse events 
included in PK/PD 
evaluation
small study. Nurses 
may not be 
reflective of general 
practice since 54% 
had BS, and 44% 
oncology certified. 
Questionnaire may 
have reflected more 
perceived practice 
than actual and may 
have prompted 
more consideration 
of PN assessment
Source of Funding ASCO/ONS Jensen
Pharma/Millennium
Pharma
none
Comments Provides standards 
for project
Published studies 
only used abdomen 
and thighs for SC 
bortezomib. No 
data on PK/PD in 
other sites (arm) 
demographics and 
BSA does not 
impact PK/PD SC 
vs IV.
Support PICO 
hypothesis
SC bortezomib has 
less PN than IV. 
Benefit to nursing 
practice, 
applicability to 
contextual practice 
is important given 
study indicating 
need for more 
knowledge about 
assessment and PN 
not frequently 
assessed.
Support PICO 
importance of SC 
for improved 
patient outcomes 
and nurse sensitive 
outcomes.
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13 14 15
Article Title Subcutaneous 
versus intravenous 
administration of 
bortezomib in 
patients with 
relapsed multiple 
myeloma: a 
randomized, phase 
3, non-inferiority 
study.
Comparison of 
pegfilgrastim 
prescribing practice 
to national 
guidelines at a 
university hospital 
outpatient oncology 
clinic
Subcutaneous 
alemtuzumab in 
fludarabine 
refractory chronic 
lymphocytic 
leukemia: clinical 
results and 
prognostic marker 
analysis from the 
CLL2H stud of the 
German chronic 
lymphoma 
leukemia study 
group
Author, year, 
Journal
Moreau, P., 
Pylpinko, H., 
Grosicki, S., 
Karamanesht, I., 
Lelu, X.,
Grishunina, M., 
Rekhtman, G., 
...Harousseau J-L 
(2011 April 19) 
Lancet Oncology 
12, 431-440 
D0I:10.1016/S1470 
- 2045(11)70081-X
Waters, G.E., 
Corrigan, P., 
Gatesman, M., & 
Smith, T.J. (2012 
Nov 6) Journal of 
0ncology Practice 
doi:
10.1200/J0P.2012. 
000662 retrieved 
from
http://jop.ascopubs.
org/content/early/20
12/11/06/J0P.2012.
000662?papetoc
Stilgenbauer, S., 
Zenz, T., Winkler, 
D., Buhler A., 
Schlenk, R.F., 
Groner, S., Busch 
R., Hensel, M., 
...Dohner, H. (2009 
August 20) Journal 
o f Clinical 
Oncology 27(24). 
3994-4001 
Doi:10.1200/JC0/2 
008.21.1128
Data Base & Key 
Words
MedLine 
subcutaneous 
bortezomib, Phase 3 
randomized
none Medline
Subcutaneous
chemotherapy
=3,424
Subcutaneous
versus intravenous
= 107
Administration 
procedure = 47 
Alemtuzumab = 4 
Bortezomib = 3 
Trastuzumab = 1
Research Design Phase III, open 
label, randomized
Retrospective 
medical record 
review
Phase II safety and 
efficacy of SC 
alemtuzumab
Level of Evidence II VI III
Study Aim/Purpose compare efficacy Determine if Evaluate safety,
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and safety of SC 
administration to 
standard IV 
administration
pegfilgrastrim is 
overprescribed in 
order to maintain 
quality and reduce 
costs
efficacy and clinical 
biomarker impact 
on outcomes
Methods/ Study 
Appraisal
2:1 randomization 
of 222 relapsed 
MM patients in 53 
centers in 10 
countries in Europe, 
Asia and 
SoAmerica. SC = 
148 IV = 74.
Record review of 
292 patients, 124 
evaluated and 88 
included for study. 
Descriptive 
statistics
109 patients 
enrolled (intent to 
treat) 103
evaluable. After IV 
dose escalation, SC 
administered 3 x 
week for up to 12 
weeks, response 
evaluated every 4 
weeks during 
treatment. 
Progression Free 
Survival (PFS) 
defined from first 
drug administration 
to disease
progression, Overall 
Survival (OS) time 
from first drug to 
death, data censored 
for patients alive at 
last follow up. Time 
to Treatment failure 
(TTTF) from first 
drug to disease 
progression, next 
treatment or death. 
Kaplan Meier 
estimation of 
response duration, 
CI based on 
cumulative hazard. 
Survival
distribution by log 
rank, Cox hazard 
regression for 
variables. Biologic 
markers by FISH.
Primary
Outcomes/Measures
/Results
non-inferiority in 
overall response 
rate as defined by
37% had no risk 
factors, 22% had 
one risk factor,
OR 39% (CR 4%, 
PR 30%) Median 
PFS 7.7 mos,
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retaining 60% of IV 
treatment effect.
OR of 35% in both 
arms or greater for a 
80% power and one 
sided alpha of 
0.025. Time to 
event with Kaplan 
Mier, adverse 
events in all 
patients receiving at 
least one dose
46% of doses were 
avoidable. Cost to 
health care system 
was $712, 264 in 1 
year
Median OS 19.1 
mos.
Toxicity profile 
similar to IV 
administration w 
mild injection site 
reactions
Author 
Conclusions/ 
Implications of Key 
Findings
OR after 4 and 8 
cycles were 
identical in SC and 
IV arms. Adverse 
events were similar 
in both arms 
EXCEPT peripheral 
neuropathy was 
lower in SC than IV 
arm (5% vs 15%). 
PK/PD reflect 
similar AUC and 
Cmax 10 times 
longer with SC.
Approximately 50% 
of pegfilgastrim use 
did not follow 
NCCN or ASCO 
guidelines for use. 
Changing practice 
will reduce cost 
without harming 
patients
SC as effective and 
save as IV data in pt 
population. “SC 
should be preferred 
delivery route 
because of efficacy, 
convenience, 
improved adverse 
effect profile, and 
cost savings” p. 394
Strengths/limitation
s
Large multi­
centered
international study. 
Limitations, no U.S. 
sites. No patient 
reported outcomes 
to support benefit of 
SC from patient 
perspective
Retrospective chart 
review in one 
institution. 
Prescribers 
background not 
identified. 
Prescribers 
knowledge of 
guidelines not 
addressed
Clinical trial does 
not describe how or 
where SC 
administered
Source of Funding Johnson & Johnson 
& Millennium 
Pharma
Comments Pivotal data 
supporting use of 
SC bortezomib as 
being effective with
Support PICO 
hypothesis that 
guidelines may not 
be followed even
Support PICO 
hypothesis of lack 
of data on how to 
administer SC
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less PN. Provides when published. chemotherapy.
guidance on Adherence to
dilution and guidelines can
administration of reduce costs
SC formulation at without patient
2.5mg/ml vs. 1:1 harm.
concentration.
Administration sites
only in abdomen
and thigh.
16 17 18
Article Title Knowledge, 
attitudes and 
practice behavior of 
oncology advanced 
practice nurses 
regarding advanced 
care planning for 
patients with 
cancer.
Subcutaneous 
administration of 
bortezomib: 
strategies to reduce 
injection site 
reactions
Using the Theory of 
Planned Behavior to 
predict nurses' 
intention to 
integrate research 
evidence into 
clinical decision­
making.
Author, year, 
Journal
Zhou, G., Stoltzfus, 
J.C., Houldin, A.D., 
Marks, S.M., Swan 
B.A. (2010 
November) 
Oncology Nursing 
Forum 37(6) p 
E400-E410 
doi:10.1188/10.ON 
F.E400-E410
Kurtin, S., Knop, 
C.S. & Milliron, T. 
(2012, Nov/Dec) 
Journal of 
Advanced Practice 
Oncology 3(6) 406­
410
). Journal o f
Advanced.
Cote, F., Gagnon, 
J., Houme, P.K., 
Abdeljelil, A.B, 
Cagnon, M-P. 
(2012)
Journal of
Advanced Nursing
68(10)2289-2doi:
10.1111/j.1365-
2648.2011.05922.x
298
Data Base & Key 
Words
ONS.org oncology 
nurses knowledge, 
practice, theory of 
planned behavior, 
valid practice 
survey
CINHAL 
subcutaneous 
bortezomib, nurse, 
administration, 
injection
CINHAL,Wiley 
Online; Theory of 
Planned Behavior, 
clinical decisions, 
apply evidence
Research Design descriptive, cross 
sectional pilot
Opinion of author predictive 
correlational study
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survey
Level of Evidence VI VII VI
Study Aim/Purpose establish reliability, 
validity of web 
based survey on 
nurses knowledge, 
attitudes and 
practice, gain 
understanding of 
nurses knowledge 
and perceived 
barriers to practice
Review of SC 
Phase III study. 
Provide
recommendation for 
SC administration 
technique
identify factors that 
influence nurses 
intention to adopt 
research into 
practice
Methods/ Study 
Appraisal
One author 
developed questions 
based on Theory of 
Planned behavior, 
using questions 
from other surveys, 
own clinical 
expertise and input 
from practice 
experts. Initial 
survey evaluated by 
6 APNs, then sent 
to 300 APNs. 89 
included in final 
analysis. After 30­
40 days re-test 
survey sent to 89 
respondents. 53 
completed. 
Information loaded 
onto excell and 
coded then put into 
SAS for stats. 
Descriptive stats for 
demographics, 
Factor analysis for 
questions for test 
and re-test with 
Cornbach alpha for 
5 factors to validate 
questionnaire. "Resu 
lts revealed a sta-
n/a
questionnaires sent 
to nurses in one 
hospital. 336 
questionnaires 
analyzed. Sample 
size was deemed 
adequate due to 
being 10 times 
higher than number 
of varialbes in the 
regression model. 
Institution was 
University setting 
with wide variety of 
settings. 
test-retest to 
validate 
questionnaire. 
Added two 
elements to TPB 1. 
past behavior and 
moral norm based 
on research done by 
authors. Descriptive 
statistics for mean 
and SD of 
scores,Pearsons 
correlations 
between outcome 
variable = intention 
and independent 
variables, multiple
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tistically significant 
correlation between 
the two surveys (r = 
0.74, p < 0.0001), 
thereby providing 
preliminary 
evidence of test- 
retest reliability." (p 
E405)
linear regression to 
identify variables 
that predict nurses 
intention to use 
research in practice 
and between beliefs 
and intentions ,
Primary
Outcomes/Measures
/Results
Knowledge of 
advanced care 
planning: average 
score was 67% (33­
92%). In general 
participants scored 
positively in 
attitudes about 
advanced care 
planning, only 
marginally positive 
in practice of 
incorporating 
advanced care 
planning. Barriers 
included family not 
ready, physicians 
reluctant, staff 
discomfort and 
time.
Recommendations: 
Site seletion 
Air sandwich
Intention predicts 
behavior and is 
based on attitudes 
(behavior beliefs), 
subjective norms 
(normative beliefs) 
and perceived 
control (control 
beliefs). Study 
suggests moral 
norms, perceived 
behavioral control, 
normative beliefs 
and past behaviors 
predict intention.
Author 
Conclusions/ 
Implications of Key 
Findings
Established 
construct validity of 
survey items 
assessing nurses 
knowledge of 
advanced care 
planning. Nurses 
moderately 
knowledgeable, and 
with positive 
attitudes. Study 
outcomes similar to 
literature for APNs 
and MDs
Need to develop 
practice guideline 
for SC bortezomib 
admniistration
Interventions to 
change behaviors 
need to be relevant 
to specific nursing 
practice and within 
the context of the 
practice. Behavior 
beliefs are not 
associated with 
intentions, 
subjective norms 
are least associated 
with behavior, 
moral norm and 
past behavior are
Subcutaneous Bortezomib 79
most associated 
with intention and 
behavior
Strengths/limitation
s
small sample. Need 
5 - 10 respondents 
per item & other 
analytics to validate 
survey
Very limited 
references utilized. 
References for air 
sandwich based on 
authors articles, not 
reference
small sample at one 
French Canadian 
institution
Source of Funding Not indicated Non indicated Canadian Institutes 
of Health Research
Comments Theory of Planned 
Behavior (TPB) 
valid for capstone 
in identifying 
perceptions and 
practice.
Supports need to 
develop SC 
injection guidelines. 
Need for more 
literature review
Strong article to 
support TPB in 
considering how 
nurses intent to use 
SC procedure. 
Reinforce nurses 
have important role 
in pt outcomes
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Article Title Understanding 
adherence to hand 
hygiene
recommendations: 
the Theory of 
Planned Behavior.
Clinicians’ 
perceptions about 
use of computerized 
protocols: a 
multicenter study
Subcutaneous 
injection technique
Author, year, 
Journal
O'Boyle, C.A. 
Henley, S.J.,
Larson, E. (2001) 
Am J Infection 
Control 29; 352-260
Phansalkar, S., 
Weir, C.R., Morris, 
A.H. & Warner,
H R. (2008) 
International 
Journal o f Medical 
Informatics 77. 
184-193
Hunter, J (2008 
January) Nursing 
Standard. 22(21) 
41-44
Data Base & Key 
Words
CINHAL, Theory 
of Planned 
Behavior, nurse, 
adherence, 
procedures
MedLine 
Clinician 
perceptions = 405 
Clinical protocols 
Decisions = 4
CINHAL 
subcutaneous 
injection, technique, 
drug administration
Research Design longitudinal,
observational
Semi structured 
interviews
none
Level of Evidence VI VI VII
Study Aim/Purpose Estimate adherence 
to hand washing 
recommendations; 
describe 
relationship 
between 
motivational 
factors, adherence 
and intensity of 
nursing activity to 
handwashing; test a 
model for 
adherence based on 
TPB
Develop and 
validate instrument 
for assessing 
clinicians 
perceptions about 
computerized 
protocols
Describe principles 
and technique for 
SC injections to 
update nurses’ 
knowledge and 
skills
Methods/ Study 
Appraisal
120 nurses in 
critical care and 
post critical care 
unit s in 4 
Minneapolis
Two stage:
1. semi 
structured 
interviews 
to identify
N/A
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hospitals.
Nurses completed 
Hand washing 
Assessment 
Inventory, 2 weeks 
- 4 months later 
were observed in 
practice for 
adherence to 
guideline. 
Descriptive 
statistics and 
correlation statistics
themes 
2. 2. Item 
generation 
for
instrument; 
administer 
instrument 
needed 5 
participants 
per item for 
power = 
sample size 
175; factor 
analysis 
using 
Varimax 
rotation and 
scree plots;, 
scale
construction 
Cornbachs 
alpha 0.70 
or higher; 
construct 
and
predictive
validity
Pearsons
correlation
Primary
Outcomes/Measures
/Results
1246 indications for 
handwashing, 
adherence 70% (61­
74%) vs self 
reported adherence 
of 82% (71-89%) 
p=0.0001. High 
correlation between 
motivational factors 
and intentions, but 
not w observed 
adherence
82% response rate 
240 clinicians (53 
physicians, 132 
nurses, 55 resp. 
therapists)
29 of 35 items 
retained
N/A
Author 
Conclusions/ 
Implications of Key 
Findings
Predicting 
handwashing 
adherence only 
occurred in the
Results provide a 
theorectical 
framework for 
assessing clinical
Step by step 
approach with 
rationale for the 
steps .
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context of specific 
nursing activities, 
and not related to 
motivational 
variables from the 
TPB.
perceptions about
computerized
protocols
Strongest predictor: 
Beliefs regarding 
self-Efficacy. 
Literature review of 
barriers to guideline 
adherence: 
Knowledge, 
attitudes and 
external barriers. 
Making clinicians 
understand why 
protocols are 
important for 
patient outcomes 
will improve 
intentions for use.
Strengths/limitation
s
Important study. 
Small sample size, 
self selected 
participants, no 
control for 
institutional 
confounding 
variables
Based on Nursing 
and Midwifery 
Council (UK).
Source of Funding Georgetown 
University School 
of Nursing, 3M 
Enrich Program, 
Association of 
Professionals in 
Infection Control 
Research 
Association
NIH/NHLBI ARDS
Comments Must focus on 
individual in 
specific context and 
situation, rather 
than on theoretical 
situation. Perceived 
control and past 
behavior can predict
Based on Theory of 
Planned Behavior. 
Factors influencing 
perceptions:
Beliefs regarding 
self-efficacy, 
environmental 
support, role
Does NOT discuss 
changing needle 
before
administration, 
important for 
chemotherapy 
administration. 
Does provide
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intention and 
behavior. Project 
should address SC 
in context of clinic 
setting and past 
experiences
relevance, work 
importance, beliefs 
regarding control, 
attitude towards 
information quality, 
social pressure, 
culture and 
behavioral intention
rationale for sites 
including the arm 
for SC
22 23 24
Article Title Management 
guidelines for the 
use of aletuzumab 
in chronic 
lymphocytic 
leukemia
Likert scales and 
data analysis
Likert scales, levels 
of measurement and 
the “laws” of 
statistics
Author, year, 
Journal
Ostergorg, A., Foa, 
R., Bezares, R.F., 
Dearden, C., Dyer, 
M.J.S., Geisler, C., 
Lin, T.S., Montillo, 
M., van Oers, 
M.H.J., Wendtner, 
C-M., (2009) 
Leukemia 23. 1980­
1988 doi:
10.1038/leu.2009.1
46
Allen, I.E., 
Seamona, C.A. 
(2007) American 
Society for Quality. 
Retrieved from 
http://asq.org/qualit
y-
progress/2007/07/st
atistics/likert-scales
Norman, G. (2010) 
Advances in Health 
Science Education 
15. 625-632. Doi: 
10.1007/s10459- 
010-922-y
Data Base & Key 
Words
MedLine
Subcutaneous
chemotherapy,
administration
Medline
Survey instruments, 
design, Likert 
scales, ANOVA, 
ordinal statistics 
methods
MedLine
Likert scales, data
analysis,
Research Design Consensus review None none
Level of Evidence VII N/A n/a
Study Aim/Purpose Update 2004 
recommendations 
based on clinical 
data
Overview of use of 
likert scales for 
rating surveys.
Challenges 
argument that 
parametric methods 
cannot be used with 
ordinal data from 
Likert scales. 
Review of 
assumptions of 
various statistical
Subcutaneous Bortezomib 84
methods and the 
problems when 
assumptions are 
violated (p 627)
Methods/ Study 
Appraisal
Consensus of 
experts
N/A n/a
Primary
Outcomes/Measures
/Results
1. monotherapy can 
be used as front line
2. describes suitable 
subgroups of 
elderly, 3.
Treatment should 
continue fo r12 
weeks, 4. Mandate 
CMV monitoring 
by PCR, 5. SC IS 
SAFE, EASY AND 
EQUALLY 
EFFICACIOUS. 6. 
Combination and 
consolidation 
should only be used 
in clinical trials.
Likert scales should 
NOT involve 
parametric statistics 
but should rely on 
the ORDINAL 
nature of the data (p 
3). Scales with even 
numbers force rank 
by eliminating the 
neutral option.
Sample Sizes:
Small sample size 
may be an issue that 
is unrelated to 
choice of statistical 
test. Too small 
sample challenges 
validity of being 
representative 
EXCEPT in 
qualitative studies. 
Small size may 
cause concern about 
distributions. 
HOWEVER the 
demarcation is 5 per 
group.
Normal distribution 
is based on the 
normality of the 
distribution of the 
means, not the data. 
Therefore, ANOVA 
can be used. The 
Central Limit 
Theory indicates for 
samples greater 
than 5 or 10 per 
group, the means 
are approximately 
normally 
distributed.
Author 
Conclusions/ 
Implications of Key 
Findings
See above Mean and standard 
deviation are 
INVALID for 
descriptive stats 
from an ordinal 
scale. NON- 
PARAMETRIC
“Parametric 
statistics can be 
used with Likert 
data, with small 
sample sizes, with 
unequal variances 
and with non-
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procedures based on 
rank, median or 
range, or 
distribution free 
methods such as 
tabulations, 
frequencies, 
contingency tables 
and chi squared 
statistics are 
appropriate.
Kruskall Wallis can 
be used for analysis 
of variance.
normal
distributions”
Strengths/limitation
s
Based on data on 
over 20,000 patients 
in clinical literature 
and NCCN 
guidelines. 
Limitation, expert 
panel opinion
Brief summary of 
likert scales and 
appropriate 
statistics
Source of Funding Conflict of interest: 
all authors had 
received honoraria 
from Bayer Pharm
Comments Although SC is 
deemed safe, 
effective and easy 
to give, there is no 
direction on how to 
administer the drug.
Useful for 
designing survey 
statistics
Provided 
clarification for 
validation of 
instrument articles 
that indicated 5 
respondents per 
question was 
needed. Provided 
confusion about 
what statistics to 
use for survey.
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Article Title Oncology nurses’ 
perceptions about 
involving patients 
in the prevention of 
chemotherapy 
administration 
errors
Nursing -sensitive 
patient outcomes -  
description and 
framework
Qualitative data 
analysis for health 
services research: 
developing 
taxonomy, themes 
and theory
Author, year, 
Journal
Schwappach,
D.L.B.,
Hochreuetener, M­
A, Wernli, M., 
(2010 March) 
Oncology Nursing 
Forum 37(2) E84- 
E91 doi:
10.1188/10.ONF.E8
4-E91
Given, B., Beck, S., 
Etland, C., Holmes 
Gobel, B., Lamkin, 
L., & Marsee, V.D. 
(2005) Retrived 
from
http://www.ons.org/ 
Research/NursingSe 
nsitive/ Description
Bradley, E.H,
Curry, L.A., & 
Devers, K.J. (2007) 
Health Services 
Research 42, 1758­
1772
doi: 10.1111/j.1475- 
6773.2006.008684.
x
Data Base & Key 
Words
CINHAL, 
Academic 
SearchPremier, 
Eric, MedLine 
Mixed methods 
design nurs* = 
1,217
And oncology nurs 
= 45
Perception 
chemotherapy= 20
ONS.org 
Nurse sensitive 
outcomes defined
MedLine, 
Academic Search 
Premier, CINHAL, 
Eric
Qualitative data 
analysis health 
care= 7,842 
Developing themes 
= 187
Research Design Descriptive
qualitative
White paper None -
Level of Evidence VI VII
Study Aim/Purpose Explore nurses’ 
attitudes, and 
experiences toward 
patients 
participation in 
preventing chemo 
administration 
errors
Provide definition 
for nursing sensitive 
outcomes in support 
of ONS
commitment to 
quality and 
defining, 
measuring, and 
educating about 
nursing sensitive 
outcomes.
Provide practical 
strategies for 
analyzing 
qualitative data
Methods/ Study 
Appraisal
Focus group 
discussion of 11 
oncology nurses
Expert panel 
consensus
“describe an 
approach to 
qualitative data
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from a large 
Swedish 
community 
hospital. 6 nurses 
from outpatient 
oncology , 5 from 
inpatient setting. 
First focus group 
discussed 
experiences with 
patients, attitudes, 
and nurses’ role in 
engaging patients in 
safety. Second 
session with same 
group 10 weeks 
later themes were 
observations and 
experiences, 
anticipated or 
perceived changes 
in relationships, 
responses and 
interventions. 
Sessions recorded 
and transcribed 
verbatim, inductive 
theme-identification 
content-analysis 
framework applied 
to transcripts, 
categories 
abstracted, iterative 
process to organize 
into themes. Results 
and interpretations 
discussed with 
focus group 
participants for 
member checking
analysis that applies 
the principles of 
inductive reasoning 
while also 
employing 
predetermined code 
types to
guide data analysis 
and interpretation. 
These code types 
(conceptual, 
relationship, 
perspective, 
participant 
characteristics, and 
setting codes) 
define a structure 
that is appropriate 
for generation of 
taxonomy, themes, 
and theory. 
Conceptual codes 
and subcodes 
facilitate the 
development of 
taxonomies”
Primary
Outcomes/Measures
/Results
Four major themes 
emerged
Involving patients; 
challenges, strains 
and barriers; 
Responsibility for
Outcomes must 
address short, 
intermediate and 
long-term 
interventions. 
Measurements must
Describe ways to 
develop and 
measure codes. 
Generating results 
through taxonomy, 
themes and theory
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safety; and learning 
and reflecting on 
patient
involvement. (p 
E86) May 
participants 
changed behavior 
between focus 
groups
take place at 
expected time of 
outcome from 
intervention. 
Outcomes 
indicators are 
patient focused and 
provider focused. 
Provider focused 
outcomes relate to 
provider 
proficiency, 
knowledge, skill, 
self-confidence, 
turnover, priority 
satisfaction and 
caregiver demands. 
Provider practice 
activities affect 
patient outcomes, 
including 
complications and 
provider 
effectiveness
Author 
Conclusions/ 
Implications of Key 
Findings
“Active
involvement of 
patients in safety 
requires cultural 
and organizational 
change” for 
success.
“Chemotherapy 
administration 
procedures should 
be standardized to 
allow patients to 
detect deviations 
from routine.” (p 
E89) TPB self­
efficacy, behavioral 
control beliefs and 
perceived 
effectiveness of 
actions supported in 
article.
Classification of 
Oncology NSO: 
Symptom 
experience 
Functional status 
Safety
Psychological
distress
Economic
“Qualitative
research
methodologies can 
generate rich 
information about 
health care 
including, but not 
limited to, patient 
preferences, 
medical decision 
making, culturally 
determined values 
and health beliefs, 
consumer 
satisfaction, 
health-seeking 
behaviors, and 
health disparities”
Strengths/limitation Single institution Provides exemplars
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s with subjects from 
two very different 
practice
environments and 
experiences. Small 
number. Did not 
describe saturation
for NSOs. White 
paper from small 
group of experts
Source of Funding Grant from 
Oncosuisse
ONS Patrick and 
Catherine Weldon 
Donaghue 
Medical Research 
Foundation and the 
Claude D. Pepper 
Older Americans 
1768 HSR: Health 
Services Research 
42:4 (August 2007) 
Independence 
Center at Yale 
University
Comments Key article to 
consider for 
qualitative 
component of 
project. Supports 
patient role in 
administration and 
importance of 
nurses consistency 
in administration 
procedures to 
ensure patient 
safety and 
confidence in 
nursing procedures.
Oncology nurses 
skills, knowledge 
and competence can 
influence SC 
administration and 
adverse events.
Provides guidance 
for developing 
themes from project 
interviews in order 
to describe nurse 
perceptions and 
decisions about 
administering SC 
chemo
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28 29 30
Article Title Three approaches to 
qualitative content 
analysis
Mixed methods
research
methodologies
Methodological 
reporting in 
qualitative, 
quantitative and 
mixed methods 
health services 
research articles
Author, year, 
Journal
Hsieh, H.F., & 
Shannon, S.E. 
(2005) Qualitative 
Health Research.
15, 1277-1288 doi:
10.1177/104973230
5276687
Terrell, S.R (2012 
Janurary)
The Qualitative 
Report 17(1) 254­
280
http://www.nova.ed
u/ssss/QR/QR17-
1/terrell.pdf
Wisdom, J.P., 
Cavalerie, M.A., 
Onwuegbuzie, A.J., 
& Green, C.A. 
(2012 April) Health 
Services Research. 
47(2) 721-745 
DOI:
10.1111/j.1475-
6773.2011.01344.x
Data Base & Key 
Words
Same as previous Eric
Mixed methods, 
qualitative research, 
methodology
MedLine, 
Academic Search 
Premier, Eric 
Mixed methods, 
health care
Research Design none None Literature summary
Level of Evidence VII
Study Aim/Purpose Delineate 
procedures to 
analyze three 
approaches for 
content analysis in 
qualitative design
Provide an 
overview of mixed 
methods in health 
care research
describes the 
frequency of mixed 
methods in 
published health 
services research 
and compares the 
presence of 
methodological 
components 
indicative of 
rigorous approaches 
across mixed 
methods, 
qualitative, 
and quantitative 
articles.
Methods/ Study 
Appraisal
“identified three 
distinct approaches: 
conventional, 
directed, and
Overview and 
background
Reviewed empirical 
articles from 4 
journals and 
determined if
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summative. All 
three approaches 
are used to interpret 
text
data from a 
predominately 
naturalistic 
paradigm”
Utilized
hypothetical data 
drawn from end-of- 
life care
qualitative, 
quantitative or 
mixed design. 
“Random samples 
of
qualitative and 
quantitative articles 
were selected using 
a random number 
generator and did 
not adjust for 
journal or year 
assessed the 
frequency of 
key methodological 
components 
reported across 
articles, then 
compared rates 
by article type.” (p 
727)
articles were coded, 
conducted a 
statistical analysis 
to determine 
whether there were 
trends over time in 
the prevalence of 
mixed methods 
articles.
Primary
Outcomes/Measures
/Results
“Key differences 
among 
conventional, 
directed, and 
summative 
approaches to 
content analysis 
center on how 
initial codes are 
developed.
In a conventional 
content
analysis, categories 
are derived from 
data during data
Four factors 
determine 
approach: 
Theoretical 
perspective: 
explicitly based on 
theory or implicitly 
indirectly based on 
theory 
Priority: 
Quantitative or 
qualitative primary 
Sequence of data 
collection: 
qualitative or 
quantitative first or
Research Question 
1: How has the 
frequency of mixed 
methods studies 
published 
in health services 
journals changed 
over time? 
from 2003 through 
2007. Only 2.85 
percent (n = 47) of 
empirical articles 
were mixed 
methods studies; 
6.18 percent 
(n = 102) of
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analysis. The 
researcher 
is usually able to 
gain a richer 
understanding of a 
phenomenon with 
this approach.
With a directed 
content analysis, the 
researcher uses 
existing theory or 
prior research 
to develop the 
initial coding 
scheme prior to 
beginning to 
analyze the data.
The summative 
approach to content 
analysis is 
fundamentally 
different from the 
prior two 
approaches.
Rather than 
analyzing the data 
as a whole, the text 
is often approached 
as
single words or in 
relation to particular 
content. An analysis 
of the patterns leads 
to
an interpretation of 
the contextual 
meaning of specific 
terms or content”
none
Point of data 
integration:
At data analysis, at 
data interpretation 
or combination
empirical studies 
represented 
qualitative research. 
Quantitative 
research
represented 90.98 
percent (n = 1,502) 
of empirical 
articles. All journals 
combined published 
an average of 10.8 
mixed method 
articles per year, or 
3.27 percent of 
empirical articles 
annually.
A quadratic trend 
was seen across the 
5 years (R2 = 0.65), 
indicating a slight 
increase in mixed 
method articles in 
the first 2 years and 
then a decrease for 
the remaining 
years.” (p 729) 
Research Question 
2: How are mixed 
methods articles 
being used to 
elucidate 
health services 
research?
Mixed methods 
articles were 
categorized into 
four overlapping 
categories:
Articles on 
organizational and 
individual decision 
making processes 
(n = 18 studies) 
combined 
qualitative 
interviews with
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quantitative 
administrative 
data analyses to 
assess decision 
making about 
processes or 
impediments 
to processes (p 
730)
Author 
Conclusions/ 
Implications of Key 
Findings
The question of 
whether a study 
needs to use a 
conventional, 
directed, or 
summative 
approach to content 
analysis can be 
answered by 
matching the 
specific research 
purpose and the 
state of science in 
the area of interest 
with the appropriate 
analysis technique” 
(p 1286)
“there are
established rules for 
controlling validity 
in standard 
quantitative and 
qualitative research. 
These same rules 
must be followed 
when the methods 
are combined.” (p 
274)
Mixed methods 
provide more 
comprehensive 
picture than the two 
methods alone. 
However, care must 
be taken to use 
rigorous 
methodologies 
“Whatever 
frameworks are 
used, it is essential 
that authors who 
engage in mixed 
methods research 
studies meet two 
primary goals 
(developed 
by the American 
Educational 
Research
Association 2006): 
Mixed methods 
researchers should 
(1) conduct and 
report research that 
is warranted or 
defensible 
in terms of 
documenting 
evidence, 
substantiating 
results, and 
validating
conclusions; and (2) 
ensure that the
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conduct of research 
is transparent in 
terms
of clarifying the 
logic underpinning 
the inquiry” (p 740)
Strengths/limitation
s
Review of over 
1,000 articles. 
Literature review, 
not systematic 
review applied to 
only four journals
Source of Funding . not indicated Not indicated National Institute 
on Drug Abuse
Comments My assumption is a 
conventional 
content analysis 
would be 
appropriate for the 
project
Assume project 
will use implicit 
theoretical approach 
based indirectly on 
theory of planned 
behavior. 
Quantitative data 
will have priority 
over qualitative. 
Data will not be 
collected in 
sequence.
Am not sure about 
data analysis
Mixed method 
useful for 
describing decision 
making process 
such as procedure 
for SC and site 
preference. 
However, following 
rigorous methods 
may be challenge a 
priori
31 32 33
Article Title A 4 mm needle 
reduces the risk of 
IM injections 
without increasing 
backflow to skin 
surface in lean 
diabetic children 
and adults
Evaluation of skin 
and adipose tissue 
thickness for 
optimal insulin 
injection.
Effect of injection 
duration on bruising 
associated with 
subcutaneous 
heparin: a quasi- 
experimental 
within-subject 
design
Author, year, 
Journal
Birkebaek, N. H., 
Solvig, J., 
Jorgensen, C., 
Smedegaard, J., & 
Christiansen, J. S. 
(2008, September). 
Diabetes Care, 
31(9), e65.
Akkus, O., Oguz, 
A., Uzunlulu, M., & 
Kizlgul, M. (2012). 
Journal Diabetes 
Metabolism, 3(8). 
http://dx.doi.org/10. 
4171/2155­
6156.1000216
Akpinar, R. B., & 
Celebioglu, A. 
(2008). 
International 
journal o f Nursing 
studies 45, 812-817
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http://dx.doi.org/
Data Base & Key 
Words
MedLine SC, 
needle size
MedLine SC, 
adipose thickness, 
needle size
CINHAL 
SC injection 
duration site 
reactions
Research Design Descriptive
intervention
Case control Quasi-experimental
Level of Evidence VI IV IV
Study Aim/Purpose Measure distance 
from from skin to 
muscle in lean DM 
pts and use of 4 mm 
needle to reduce 
frequency of IM 
compared to 6 mm
Compare skin and 
SC adipose tissue 
between health 
controls and DM 
pts and associates 
BMI and waist 
circumference
Compare the effects 
of 3 SC injection 
durations on 
bruising
Methods/ Study 
Appraisal
21 lean children / 
32 lean adults
36 subjects received 
3 injections from 
same investigator 
using 3 techniques 
descriptive statistics
Primary
Outcomes/Measures
/Results
No distance < 4 mm 
from skin to fascia 
in abdomen or 
thigh.
Highest skin and 
adipose tissue 
thickiness 
associated with 
higher waist 
circumference and 
BMI
30 second injection 
and waiting 10 
seconds before 
withdrawing after 
10 second injection 
resulted in less 
bruising than 10 
second
Author 
Conclusions/ 
Implications of Key 
Findings
4 mm needles 
reduce risk of IM 
can inject without 
elevated skin fold 
using 90 degree 
angle in thigh 
Use 45 degree angle 
and skin fold with 6 
mm needle in thin 
pts
Largest skin 
thickness 3.92 mm 
Short needles 
appropriate in pts w 
> BMI 
Average skin 
thickness 
Arm: 1.95 mm 
Abdomen 2.35 mm 
Thigh 1.97 mm 
SC adipose tissue 
Arm 6.42 mm 
Absomen 15.73 
Thigh 7.92
Slow injection 
causes low 
pressure, less 
trauma. Waiting to 
withdraw needle 
may allow 
absorption.
Strengths/limitation
s
Small study, 
abstract summary
Source of Funding Novo Nordisk
Comments Supports use of Use of needles > Evidence of nursing
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needles < 5mm for 6mm without practice to decrease
SC pinching skin or bruising
with 90 degree 30 sec injection OR
angle may = IM 10 sec injection
leaving needle in
for 10 sec
34 35 36
Article Title A study on the 
effect of the 
duration of 
subcutaneous 
heparin injection on 
bruising and pain
Does needle size 
matter?
Skin and 
subcutaneous 
adipose layer 
thickness in adults 
with diabetes at 
sites used for 
insulin injections: 
implications for 
needle length 
recommendations
Author, year, 
Journal
Zaybak, A., & 
Khorshid, L. (2007 
Journal of Clinical 
Nursing 378-385 
doi.org/10.111/j.13 
65­
2702.2006.01922
Gill, H. S., & 
Prausnitz, M. R. 
(2007, September). 
Journal o f Diabetes 
Science adn 
Technology, 1(5), 
725-729.
Gibney, M. A., 
Arce, C. H., Bryon, 
K. J., & Hirsch, L. 
J. (2010). Current 
Medical Research 
& Opinion, 26(6), 
1519-1530.
Data Base & Key 
Words
CINHAL
SC, pain, bruising,
duration,
CINHAL 
SC needle size, 
needle gauge, pain, 
needle insertion
Research Design Quasi experimental 
within patient
Review article
Level of Evidence IV VII
Study Aim/Purpose Determine effect of 
injection duration 
on bruising and 
pain
Review
development of 
smaller needles
Methods/ Study 
Appraisal
50 pts SC heparin 
administered 10 
seconds and 30 
seconds Visual 
Analog Scale to 
measure pain
Primary 10 second injection Likelihood of pain
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Outcomes/Measures
/Results
= 64% bruising 
30 second = 42%
pain significantly 
lower with 30 sec 
vs 10 sec
and bruising 
decreases with 
higher gauge 
needles 
Mechanics of 
needle insertion, 
force of insertion 
also impacts pain
Author 
Conclusions/ 
Implications of Key 
Findings
Duration has effect 
on bruising and 
pain
Strengths/limitation
s
Source of Funding
Comments Extend injection 
duration
Needle tip 
sharpness, 
lubrication can 
reduce the force of 
insertion
Suggests rationale 
for needle change 
after drawing up 
medicatioin
37 38 39
Article Title Performing 
subcutaneous 
injections: a 
literature review.
Adherence to 
therapy: Using an 
evidence-based 
protocol
Evaluation of 
bruises and areas of 
induration after two 
techniques of 
subcutaneous 
heparin injection
Author, year, 
Journal
Annersen, M., & 
Wilmann, A. (2005, 
Third Quarter). 
Worldviews on 
Evidence-Based 
Nursing, 122-130.
Moore, L. A., 
Kaufman, M. D., 
Algozzine, R., Irish, 
N., Martin, M., & 
Posey, C. R. (2007, 
November/Decemb 
er). Rehabilitation 
Nursing, 32(6), 
227-232.
Wooldridge, J. B.,
& Jackson, J. G. 
(1988, September). 
Heart & Lung 17(5) 
476-482
Data Base & Key 
Words
Research Design Systematic Review
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Level of Evidence I
Study Aim/Purpose
Methods/ Study 
Appraisal
Primary
Outcomes/Measures
/Results
Author 
Conclusions/ 
Implications of Key 
Findings
Strengths/limitation
s
Source of Funding
Comments Most significant 
reference: Need to 
describe what 
nurses are doing
Evidence for air 
sandwich and dry 
needle
Change needle and 
use of air bubble
40 41 42
Article Title
Management 
strategies for 
improving the 
tolerability of 
interferons in the 
treatment of 
multiple sclerosis.
Randomized 
clinical trial to 
assesspain and 
brising in medicines 
administered by 
means of 
subcutaneous and 
intramuscular 
needle injections: is 
it necessary to have 
needles changed?
Effects of changing 
needles prior to 
administering 
heparin
subcuatneously.
Author, year, 
Journal
Girouard, N., & 
Theoret, G. (2008). 
Canadian Journal of 
Neuroscience 
Nursing 30(4) 18­
24
Lamblet, L. C., 
Meira, E. S., 
Ferreira, B. C., & 
Mathucchi, S. D. 
(2011,
September/October) 
. Latino-American 
Enfermagen, 19(5), 
1063-1071.
Kingman, L. (2000, 
Jan-Feb). Heart 
Lung, 29(1), 70-75.
Data Base & Key 
Words
Research Design
Level of Evidence
Study Aim/Purpose
Methods/ Study
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Appraisal
Primary
Outcomes/Measures
/Results
Author 
Conclusions/ 
Implications of Key 
Findings
Strengths/limitation
s
Source of Funding
Comments Site rotations and 
needle change
RCT no advantage 
to needle change
No decrease in 
bruising w needle 
change
43 44 45
Article Title Patient education: 
Giving a 
subcutaneous 
injection.
New injection 
recommendations 
for patients with 
diabetes.
Higher incidence of 
injection site 
reactions after 
subcutaneous 
bortezomig 
administration on 
the thigh compared 
with the abdomen
Author, year, 
Journal
National Institutes 
of Health. (2012). 
www.cc.nih.gov/cc 
c/pati ent_educati on/ 
pepubs/subq.pdf
Frid, A., Hirsch, L., 
Gaspar, R., Hicks, 
D., Kreugel, G., 
Liersch,
J.,...Strauss, K. 
(2010).
Diabetes & 
Metabolism, 36, S3- 
S18.
Kaminura, T., 
Miyamoto, T., 
Yokota, N., 
Takashima, S., 
Chong, Y., Ito, Y., 
& Akashi, K. 
(2012). European J 
Heamatology 
http://dx .doi .org/10.
1111/ejh.12
055
Data Base & Key 
Words
Research Design Systematic review
Level of Evidence I
Study Aim/Purpose
Methods/ Study 
Appraisal
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Primary
Outcomes/Measures
/Results
Author 
Conclusions/ 
Implications of Key 
Findings
Strengths/limitation
s
Source of Funding
Comments 5/8 inch needle Short needle, 
change needle 
purge
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46 47 48
Article Title Pain following 
controlled 
cutaneous insertion 
of needles with 
different diameter
Evidence-based 
practice guidelines: 
A survey of 
subcutaneous 
dexamethasone 
administration.
New injection 
recommendations 
for patients with 
diabetes.
Author, year, 
Journal
Arendt-Neilsen, L., 
Egekvist, H., & 
Bjerring, P. (2006, 
March/June). 
Somatosensory and 
Motor Research, 
23(1/2), 37-43.
Walker, J., Lane, P., 
& McKenzie, C. 
(2010). 
International 
Journal of 
Palliative Nursing, 
16(10), 494-498
Frid, A., Hirsch, L., 
Gaspar, R., Hicks, 
D., Kreugel, G., 
Liersch,
J.,...Strauss, K. 
(2010) Diabetes & 
Metabolism, 36, S3- 
S18.
Data Base & Key 
Words
Research Design Systematic review
Level of Evidence I
Study Aim/Purpose
Methods/ Study 
Appraisal
Primary
Outcomes/Measures
/Results
Supports use of <5 
mm needles
Author 
Conclusions/ 
Implications of Key 
Findings
Strengths/limitation
s
Source of Funding Supports need for 
standard SC admin 
guidelines in 
palliative care
Recommends 
needle change and 
purge needle
Comments
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49 50
Article Title Intramuscular 
injections: To swab 
or not to swab
WHO best practices 
for injections and 
related procedures 
toolkit.
Author, year, 
Journal
Cocoman, A., & 
Murray, J. (2010) 
Retrieved from 
http://www.inmo.ie/ 
MagazineArticle/Pri 
ntArticle/6696
World Health 
Organization. 
(2010).
Data Base & Key 
Words
Research Design
Level of Evidence
Study Aim/Purpose
Methods/ Study 
Appraisal
Primary
Outcomes/Measures
/Results
Author 
Conclusions/ 
Implications of Key 
Findings
Strengths/limitation
s
Source of Funding ETOH irritating, 
not needed, if  used, 
must dry
Does not
recommend ETOH 
for SC injections 
Water cleanse
Comments
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Appendix B
The Subcutaneous Administration of Bortezomib Guideline Project Logic Model
Will the development of a standardized guideline for nurses who administer subcutaneous 
bortezomib in community oncology practice settings lead to standardized practice when 
administering this chemotherapy agent?
RESOURCES ACTIVITIES OUTPUTS SHORT &
LONG-TERM
OUTCOMES
IMPACT
In order to 
accomplish our 
set o f activities 
we will need the 
following:
A value 
proposition 
proposal for 
stakeholder buy 
in
Identification 
and acceptance 
o f cross 
functional 
project team 
(internal)
The
Subcutaneous 
Administration 
o f bortezomib 
Survey (SABS)
Evaluate and 
contact
potential study 
sites
Identify and 
select clinical 
sites agreeing 
to participate in 
project
In order to 
address our 
problem or 
asset we will 
accomplish the 
following 
activities:
Champion
project
proposal
through
required
committees
Submit and 
activate SOW 
for funding
Contract with 
clinics capable 
ofparticipating
Obtain 2 way 
CDA with 
site(s)
Develop SABS
Submit SABS 
for content 
validity review 
and amend as 
needed
Submit SABS to
We expect that 
once
accomplished 
these activities 
will produce 
the following 
evidence o f 
service 
delivery:
RNs will utilize 
standard 
guideline for 
administering 
SC bortezomib 
relative to:
Site selection
Needle size
Changing 
needles before 
administering 
injection
Use o f air
sandwich
technique
Duration o f 
injection
We expect that if 
accomplished 
these activities 
will lead to the 
following 
changes in 1-3 
then 4-6 years:
1 -  3 years: 
Standard 
guidelines for 
SC bortezomib 
will be 
incorporated 
into the clinical 
literature as a 
framework for 
standardizing 
techniques in 
community and 
academic sites. 
Hypothesis 
generating for 
pharmacokinetic 
study to 
evaluate PK of 
injections in 
arm ensuring 
safe, effective 
site selection 
4 -  6 years: 
Guidelines and
We expect that 
if  accomplished 
these activities 
will lead to the 
following 
changes in 7-10 
years:
Patients staying 
on effective 
therapy with 
reduced 
adverse events 
will obtain 
maximum 
benefit 
including 
responses and 
survival.
Produce 
exemplar for 
pharmaceutical 
companies to 
describe how 
drugs are 
administered 
during clinical 
trials, in 
addition to 
standard 
outcomes data. 
Increased
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Budget for 
study
Mechanism for 
collecting data 
from survey 
instruments
Approval from 
Global 
Medical 
Affairs, legal 
and compliance
IRB exemption 
Regis and 
Clinical 
Network
Method to 
identify nurses 
meeting 
eligibility 
criterion
Mechanism to 
present, explain 
and encourage 
participation
legal
Obtain IRB 
exemptions
Reformat SABS 
to web based 
survey format
Educate site 
coordinator, 
explain and 
provide cover 
letter,
confidentiality 
agreement and 
project process 
information
Establish 
weekly contact 
with site 
coordinator
Receive Excell
spreadsheets
with
aggregated
data
Review
spreadsheet for 
missing data
Submit
spreadsheets to 
biostatisticians, 
indicating 
missing data 
points
Perform 
content analysis 
on qualitative 
responses
Collaborate 
with clinical 
advisor to 
identify themes
Analyze data
project will 
become 
hypothesis 
generating for 
clinical studies 
to validate the 
guideline results 
in decreased 
injection site 
reactions and 
pain. Supports 
nurse sensitive 
patient 
outcomes of 
managing 
adverse events
inclusion of 
nursing 
outcomes 
studies 
incorporated 
into clinical 
trials for drug 
development 
Improved 
patient 
outcomes as 
nursing 
standards are 
included and 
described in 
clinical trials.
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Present
descriptive data 
and summary of 
qualitative 
themes to 
advisors
Formulate 
interpretations 
of data for each 
variable
Compare/ 
contrast data to 
clinical 
literature
Construct 
guidelines for 
each pertinent 
variable based 
on clinical 
literature and 
survey 
responses
Draft practice 
guideline for 
SC
administration 
o f bortezomib
Present data, 
interpretations 
and draft 
guideline to 
participating 
network clinical 
coordinators 
for review, 
discussion and 
revisions
Develop final 
guideline (2 
additional 
drafts)
Present, 
explain and
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instruct final 
guideline to 
network clinical 
coordinators
Engage in
sessions to
recommend
methods for
implementing
practice
improvement
guideline and
monitor
acceptance
Follow up with 
clinical
coordinators in
3 months to 
evaluate 
implementation 
and acceptance 
ofpractice 
guideline
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Appendix C 
Time Frame for Completion by August 2013
Aug 2012 
Redefined 
CapstoneProject 
Approval DNP 
Advisors
Sept 2012- April 
2013 Systematic 
Review of
Nov 2012 - April 
2013 Revisions 
IRB document
Literature
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Feb - March 
2013 Develop 
Survey 
Instrument
March 11 
submit NE 
IRB
March Survey 
content 
validated
March CCE 
agrees to 
project
April 9 DNP 
Capstone 
Presentation 
& NE IRB 
Approval
Feb - April April 12 Regis
Proposal IRB
Paper submitted 
Writing
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May 
Adapt 
Survey to 
web 
format
May 20 
launch 
survey
June - July 
Analyze & 
interpret 
data
^  • • • •
May Regis 
IRB 
approval
June 15 
Close 
Survey
July First Draft 
Guideline 
Presented to CCE
August 12 Present 
capstone project 
for approval 
Completion DNP 
Program
• • •
August finalize 
paper
Appendix D  
Budget and Resources
Estimated budget for the project $23,000.
Direct Costs:
• New England IRB $600
• Survey Monkey subscriptions $204
• Administrative support to convert survey to electronic format $300 
Indirect costs:
Salary for project investigator time over 20 weeks (March through June 2013) for 
approximately 15 hours per week (300 hours) at $73 per hour. Activities included:
• Draft survey
• Collaborate with content experts and redraft survey
• Prepare IRB documents for New England and Regis University IRB
• Consult with CCE on implementing survey
• Supervise administrative assistant to translate paper document to web format
• Weekly phone conversations with CCE manager of research
• Access final aggregated survey
• Evaluate survey for completeness
• Consult with statisticians to run SAS
• Analyze quantitative responses
• Analyze qualitative responses for themes
• Compare survey results to literature
• Develop draft guideline
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• Review results and draft guideline with CCE
• Develop final guideline
• Discuss final guideline with CCE for implementation
• Develop and present summary of results to Millennium Global Medical Affairs
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Appendix E
Sponsor of Survey: Jasmine Martin, MSN, APRN 
303-973-5768
Purpose: The purpose of this survey is to understand oncology nurses practice, opinion and 
perceptions about administering subcutaneous bortezomib at Cancer Clinics of Excellence. This 
survey is being done in partial fulfillment for a Doctor of Nursing program at Regis University. 
The information that is gained from your participation will be used to contribute to oncology 
nursing practice and provide information about content needed for developing a standardized 
guideline for administering subcutaneous bortezomib at Cancer Clinics of Excellence. This 
project may improve patient care and quality outcomes by reducing injection site reactions and 
pain for patients receiving subcutaneous bortezomib. Information from the project may be used 
in future presentations or publications.
All of your responses will be anonymous and confidential; no identifying information will be 
linked to you in any way.
Participation: You have been selected to participate in this survey because you have 
administered subcutaneous bortezomib in 2012. Your participation is voluntary. By completing 
this survey you consent to participate. If you choose not to participate, simply do not complete 
the survey. There is no consequence to your position or practice for not participating; you will 
not be compensated for your participation.
Directions:
• This survey will take approximately 20 minutes to complete.
• Please answer each question as completely as possible based on your own experience 
with, and opinion or perception about administering subcutaneous bortezomib.
• Most questions are multiple choices.
• Some questions request a brief, concise explanation for your response.
• There are no right or wrong answers; the purpose is to describe your personal practice, 
opinion and perception.
Thank you again for your participation in this survey.
Subcutaneous Administration of Bortezomib Survey
Section I
Questions 1 -  6 ask about your oncology and nursing experience. All information will be 
aggregate; no information can be linked directly to the participants.
1. Highest nursing degree I have earned is:
a. ADN
b. BSN
c. MSN
d. MSN, NP
e. MSN, CNS
f. DNP
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g. PhD Nursing
Other degree -  please describe
2. I am certified by the Oncology Nursing Certification Corporation (ONCC) or other 
nursing certification organization as: (check all that apply)
a. I am not certified by a credentialing organization
b. OCN
c. AOCNP
d. AOCNS
e. AOCN
f. CPHON
g. CBCN
h. APRN -  BC 
Other -  please describe
3. I have been practicing oncology nursing for
a. Less than 1 year
b. 1-5 years
c. 6 -  10 years
d. 11- 20 years
e. > 20 years
4. I have been in nursing for
a. Less than 1 year
b. 1-5 years
c. 6 -  10 years
d. 11- 20 years
e. > 20 years
5. Gender
a. Male
b. Female
6. My age is
a. Less than 21 years old
b. 21-29 years old
c. 30-39 years old
d. 40-49 years old
e. 50-59 years old
f. 60 or older
Section II
Questions 7 -  28 ask about your personal experience administering subcutaneous 
bortezomib in the clinic. Please choose the answer that most closely describes your 
experience and explain your answer when requested.
7. Who is responsible for ordering bortezomib will be administered by the subcutaneous 
route? (Circle all that apply)
a. Oncologist
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b. Nurse Practitioner
c. Clinical Pharmacist
8. Are you able to provide input into the decision regarding route of administration for 
delivering bortezomib to patients?
a. Always
b. Sometimes
c. Rarely
d. Never
9. To approximately how many patients do you administer subcutaneous bortezomib 
in a month?
a. 1 -  5
b. 6 -  10
c. More than 10
10. To approximately how many patients do you administer intravenous bortezomib in a 
month?
a. 1 -  5
b. 6-10
c. More than 10
11. How often are you responsible for the reconstitution/preparation of bortezomib?
a. Always
b. Sometimes
c. Rarely
d. Never
12. What anatomical sites do you use to administer subcutaneous bortezomib? (circle all 
that apply)
a. Abdomen
b. Thigh
c. Arm
13. What site do you prefer to administer subcutaneous injections of bortezomib?
a. Abdomen
b. Thigh
c. Arm
14. Why do you prefer the above site for injections?
15. Do you document site of injection?
a. Yes
b. No
16. How do you rotate SC injection sites?
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a. Rotate to different anatomical sites (ie abdomen to thigh and thigh to 
abdomen)
b. Rotate injection sites within same anatomical area (ie rotate injections on the 
abdomen)
c. Rotate per nurses discretion (no designated pattern of injection site rotation)
d. No rotation of injection site, use site previously used
17. Do you have an anatomical map in the patient chart to guide site rotation for each 
injection?
a. Yes
b. No
18. What site preparation do you use prior to administering the injection? (check all that 
apply)
a. Ice
b. Alcohol prep
c. EMLA cream
d. None
e. Other -  please describe
f.
19. What size needle do you use for administering the subcutaneous injection?
a. 25 gauge needle that is 5/8 inch or shorter
b. 25 gauge needle that is longer than ^  inch in length
c. What ever needle the reconstituted drug comes with
d. Unsure
20. Do you routinely put a new needle on the syringe before administering the injection?
a. Yes
b. No
21. What angle do you use to administer the SC injection when using a 4 -  6 mm needle?
a. 45 degree
b. 90 degree
22. What angle do you use to administer the SC injection when using a >6 mm needle?
a. 45 degree
b. 90 degree
23. What do you do to inject into adipose tissue
a. Pinch the skin to a tent
b. Administer in fatty areas
c. Other 
Please describe
24. Prior to injecting the drug do you
a. Expel air from the syringe
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b. Pull air into the syringe 
Please explain your rationale
25. Approximately how long does it take to administer each ml of subcutaneous 
bortezomib injection?
a. 3 -  5 seconds
b. 5 -  10 seconds
c. 10-30 seconds
d. More than 30 seconds
e. It depends on (explain)
f.
26. Do you routinely apply pressure to the site after the injection?
a. Yes
b. No
27. Does this oncology clinic have a standard guideline for administering subcutaneous 
bortezomib?
a. Yes
b. No
c. Unsure
28. The technique you use to inject subcutaneous bortezomib is based on (check all that 
apply):
a. My clinical experience
b. Clinical practice guidelines
c. Demonstration from colleagues
d. In-service or education seminar -  please describe
e. Other -  please describe
Section III
Questions 29 -  38 explore your opinion about administering subcutaneous bortezomib. 
Please choose the answer that most closely describes your opinion and explain your answer 
when requested.
29. Overall, is there a difference in the time it takes to administer subcutaneous versus 
intravenous bortezomib?
a. Much less time for subcutaneous
b. Somewhat less time for subcutaneous
c. Somewhat more time for subcutaneous
d. Much more time for subcutaneous 
Please explain your answer
30. Overall, in your clinical opinion, is the subcutaneous route more or less convenient 
for nurses to administer than the intravenous route?
a. Subcutaneous is much more convenient
b. Subcutaneous is somewhat more convenient
c. Subcutaneous is somewhat less convenient
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d. Subcutaneous is much less convenient 
Please explain your answer
31. For patients who have received both intravenous and subcutaneous bortizomib, what 
route of administration do you believe patients prefer?
a. Prefer intravenous
b. Prefer subcutaneous
c. No preference 
Please explain you answer
32. For patients receiving subcutaneous bortezomib, what site do you believe they 
generally prefer for the injections?
a. Abdomen
b. Thigh
c. Arm
33. Why do you believe patients generally prefer the above site for injections?
34. In your clinical opinion, do privacy concerns for patients receiving the injection 
influence subcutaneous injection site selection?
a. Yes
b. No
c. Please explain
35. What is the layout in your facility where subcutaneous injections are primarily
given?
a. Private examination room
b. Open infusion suite with chairs
c. Open infusion suite with curtains around each chair
d. Nurses station
e. Other: please describe
36. Your clinical decision determines where to administer subcutaneous bortezomib 
injections
a. Completely agree
b. Somewhat agree
c. Somewhat disagree
d. Disagree completely
37. The patient’s preference determines where to administer subcutaneous bortezomib 
injections
a. Completely agree
b. Somewhat agree
c. Somewhat disagree
d. Disagree completely
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38. If your technique for administering subcutaneous bortezomib differs from a practice 
guideline developed by Cancer Clinics of Excellence (CCE), you would change your 
technique to be consistent with the guidelines
a. Completely agree
b. Somewhat agree
c. Somewhat disagree
d. Disagree completely 
Please explain your answer
Section IV
Questions 39-44 are about your practice setting and your perception of the practice. Please 
choose the answer that most closely describes your perceptions. Because these questions 
explore your perceptions, please briefly explain your answers.
39. All the nurses in this clinic use the same technique to administer subcutaneous 
bortezomib.
a. Completely agree
b. Somewhat agree
c. Somewhat disagree
d. Completely disagree 
Please explain your answer
40. It is important to patients that all nurses follow the same technique when 
administering subcutaneous bortezomib.
a. Completely agree
b. Somewhat agree
c. Somewhat disagree
d. Completely disagree 
Please explain your answer
41. Patients have noticed and commented that there are differences in techniques 
between nurses administering subcutaneous bortezomib.
a. Completely agree
b. Somewhat agree
c. Somewhat disagree
d. Completely disagree 
Please explain your answer
42. It is important to the physician(s) that all nurses follow the same technique when 
administering subcutaneous bortezomib.
a. Completely agree
b. Somewhat agree
c. Somewhat disagree
d. Completely disagree 
Please explain your answer
43. A practice guideline is important in this clinic to standardize how and where 
subcutaneous bortezomib will be administered.
Subcutaneous Bortezomib 119
a. Completely agree
b. Somewhat agree
c. Somewhat disagree
d. Disagree completely 
Please explain your answer
44. If other nurses in this clinic are using techniques for administering subcutaneous 
bortezomib that differed from a CCE practice guideline, they would change their 
techniques to be consistent with the guidelines.
a. Completely agree
b. Somewhat agree
c. Somewhat disagree
d. Disagree completely 
Please explain your answer
Thank you again fo r  your time and consideration to these questions.
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Appendix F
Institutional Board Approvals and CITI Certificate
Approval of Submitted Proposal...
Institutional Review Board
This message was sent with High importance.
You forwarded this message on 5/16/2013 5:01 PM.
Sent:Thursday, May 16, 2013 3:36 PM 
To: Martin, Jasmine R
Cc: Ernst, Diane M; Gilbert, Marcia a.; Institutional Review Board 
Dear Ms. M artin...
The Institutional Review Board has thoroughly reviewed your protocol submission, 
supplementary materials, and site approval letter for your study entitled Subcutaneous 
Administration o f Bortezomib Practice Improvement Project. I am pleased to inform you that 
the study has been approved as an Exempt proposal per Category # 2. You may begin study 
implementation and data collection upon receipt of this email. An official letter of approval for 
your study files will be forthcoming. We wish you success with your planned investigation!
Patsy McGuire Cullen, PhD, CPNP 
Chair, Institutional Review Board 
(303) 964-5132 
pcullen@regis.edu 
irb@regis.edu
For IRB -  Summary Paragraph outlining an Evidence Based Practice Project
This project is an evidence-based practice (EBP) project in which a quality improvement plan, 
program evaluation, or simple educational or standard of care intervention (with a pre-test and 
post-test evaluation) will be completed. The project will be internal to an agency and inform the 
agency of issues in health care quality, cost, and satisfaction. The results from this project are not 
meant to generate new knowledge or be generalizable across settings but address a specific 
population, at a specific time, in a specific agency. These projects translate and apply the science 
of nursing to the health care field. EBP Projects utilize the acronym “PICO” rather than using a
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hypothesis. PICO stands for: P -  Population or disease; I -  Intervention or Issue of Interest; C -  
Comparison or Current Practice; and O -  Outcome. Some PICO projects will not include the 
“C.” Each PICO can be written in the form of a question and will use this template to write the
question: In ___Oncology nurses in the Cancer Clinics o f Excellence Network who have
administered Subcutatnous bortezomib_____________(P), how does__ techniques in a practice
guideline_________________ (I) compared to/with___ current practice as described from survey
results____________________ (C) affect/influence/predict adoption o f a practice
guideline________________ (O)? (Melnyk & Fineout-Overholt, 2011, p. 31)
April 9, 2013 
Jasmine Martin, MSN 
Cancer Clinics of Excellence 
5750 DTC Parkway Suite 101 
Greenwood Village, CO
RE: NEIRB# 13-131: "Subcutaneous Administration of Bortexomib: A Nurse Survey"
Dear Ms. Martin:
This is to inform you that New England Institutional Review Board (NEIRB) has reviewed the 
claim of exemption for the above-captioned project. NEIRB has determined that this research 
activity, as conducted at the above location, is exempt from NEIRB review, under the following 
categories:
□  Research involving the use of survey procedures or interview procedures or observation of 
public behavior for which subjects cannot be identified, OR release of the information would not 
be harmful to the subject.
Amendments and or changes to the research must be submitted to NEIRB for review, as changes 
may affect the exempt status.
Please call me if you have any questions about the terms of this determination.
Erin Brower, MS, CIP 
Director
Copy: NEIRB Chair
Traci Kalberer, Cancer Clinics of Excellence
85 Wells Avenue . Suite 107 . Newton, MA 02459 Phone: 617-243-3924 . Fax: 617-969-
1310 www.neirb.com
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CITI Collaborative Institutional Training Initiative 
Human Research Curriculum Completion Report 
Printed on 7/24/2013
Learner: Jasmine Martin (username: jasminemartin)
Institution: Regis University
Contact Information 1921 W Sanibel Ct
Littleton, CO 80120
Department: Nursing, DNP program
Phone: 303-973-5768
Email: jasminemartin@comcast.net
Social Behavioral Research Investigators and Key Personnel:
Stage 1. Basic Course Passed on 08/04/12 (Ref # 8400736)
Required Modules 
Date
Completed
Introduction 08/04/12 no quiz
History and Ethical Principles - SBE 08/04/12 4/5 (80%)
The Regulations - SBE 08/04/12 5/5 (100%)
Assessing Risk - SBE 08/04/12 5/5 (100%)
Informed Consent - SBE 08/04/12 5/5 (100%)
Privacy and Confidentiality - SBE 08/04/12 4/5 (80%)
Regis University 08/04/12 no quiz
For this Completion Report to be valid, the learner listed above must be 
affiliated with a CITI participating institution. Falsified information and 
unauthorized use of the CITI course site is unethical, and may be 
considered scientific misconduct by your institution.
Paul Braunschweiger Ph.D.
Professor, University of Miami 
Director Office of Research Education 
CITI Course Coordinator
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Appendix G 
Permissions and Agency Letters of Support
RE: Request for permission to use graphics in a CDA publication 
CaroleAnn Maloney [caroleann_maloney@bd.com]
You replied on 7/12/2013 8:25 AM.
Sent: Wednesday, July 10, 2013 11:15 AM
To: Martin. Jasmine R
U d ERMEPLI SER45 Office.iou (199 KB): i J PLI-INCORRECT Office.jpg
(120 KB): B p l i  -CORRECT Office.jpg (106 KB): U P N  sizes Press.jpg (2
Attachments: ^ ^  i j iNJ ZONESHF Office.jpg (142 KB): U FIT figure 10 (skin
thickn~l.JPG (48 KB): site rotation scheme FIT.PNG (261 KB): LJ 
BD4181 FIT CANADA pg!4 ILL.jpg (238 KB)
Yes, you have our permission to use these photos with the following credit: Photos courtesy of 
Forum for Injection Technique (FIT) Canada 2013
See attached the requested photos.
Good luck!
CaroleAnn Maloney, RD, CDE 
Clinical Education Specialist
BD Medical - Diabetes Care
2100 Derry Rd. W, Suite 100 Mississauga, ON L5N 0B3 
Office: 905-288-6246 Mobile: 905-965-0838 Fax: 905-288-6006 
Email: CaroleAnn_Maloney@bd.com Website: www.BD.com
RE: Request to use TPB diagram 
Icek Aizen [aizen@psych.umass.edu]
Sent:Wednesday, December 05, 2012 7:03 AM 
To: Martin, Jasmine R 
Dear Jasmine Martin,
The theory of planned behavior is in the public domain. No permission is 
needed to use the theory in research, to construct a TPB questionnaire, or 
to include an ORIGINAL drawing of the model in a thesis, dissertation, 
presentation, poster, article, or book. If you would like to reproduce a 
published drawing of the model, you need to get permission from the 
publisher who holds the copyright. You may use the drawing on my website
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(http://www.people.umass.edu/aizen/tpb.diag.html) for non-commercial 
purposes so long as you retain the copyright notice.
Best regards,
Icek Ajzen, Professor Emeritus 
University of Massachusetts 
Amherst, MA 01003 
http://www.people.umass.edu/aizen
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RE: Request regarding The Neutropenia Oncology Nurses Survey 
Anita Nirenberg [anirenbe@hunter.cuny.edu]
You forwarded this message on 12/11/2012 11:17 AM.
Sent: Tuesday, December 11, 2012 9:43 AM
To: Martin, Jasmine
NONS survev.doc (57 KBUOpen as Web Page!Attachments:
Hi Jasmine,
So, here it comes.
I would like to see how you're adapting the instrument and that you will give proper 
acknowledgement (I know that you will).
Take good care of my "baby".
Good luck 
Anita
Anita Nirenberg DNSc, RN, PNP, BC, AOCNP 
William Randolph Hearst Professor of Clinical Nursing 
Hunter-Bellevue School of Nursing, Hunter College 
City University of New York 
425 East 25th St 
New York, NY. 10010
212 481-4359: email:anirenbe@hunter.cuny.edu
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■ C ANC ER  CLIN ICS O F  EXCELLENC
Jasmine Martin, MSN, APRN 
1921 W Sanibel Ct.
Littleton, CO 80120
May 2, 2013
Dear Jasmine,
Cancer Clinics of Excellence (CCE) Is a network of twenty-two community 
based Medical Oncology practices from fourteen unique states. The mission of 
our network is to provide evidence based, personalized care to patients in their 
community. Our practices participate in clinical trials and studies to improve care 
and provide cutting edge treatments for our patients.
Your request to survey nurses (RNs) within our network administering SC 
bortezomib (Velcade), and describe their opinions and perceptions of SC 
bortezomib is approved. Wo hope that the Insight provided will assist in 
improving patient care, patient experience and clinical outcome.
CCE would like to review any presentations or publications created that 
reference CCE or are based on the CCE survey data prior to final presentation or 
publication.
CCE supports your efforts and we look forward to sharing improvement 
opportunities with our practice staff.
Please feel free to contact me if you have additional information needs. 
Sincerely,
Nancy Beegle
Cancer Clinics of Excellence 
VP of Clinical Operations 
nbeBKlg@ ccg. us .com 
303-220-9951
From: Solomon, Stefanie
To: nbeegle@cce.com
Cc: Martin, Jasmine
Subject: Millennium Study
Date: Wednesday, May 01, 2013 6:41:35 PM
Ms. Beegle,
This note is in regard to the subcutaneous bortezomib nursing survey sponsored by Millennium 
Pharmaceuticals. In addition to the corporate use of the survey data, we are aware that Jasmine 
Martin, DNPc, MSN, will be using these data as part of her doctoral program at Regis 
University.
Please let me know if you have any questions.
Best regards,
Stefanie Solomon 
Sr Counsel
Millennium Pharmaceuticals, Inc.
The Takeda Oncology Company 
40 Landsdowne Street 
Cambridge, MA 02139 
Ph:(617) 551-2948
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Appendix H
The Subcutaneous Administration of Bortezomib Practice Guideline
Cancer Clinics of Excellence
Date Issued: July 10, 2013
Last Revised: July 31, 2013 by Jasmine Martin, DNP, MSN, APRN 
Approved by:
DISCLAIMER: THE PROCEDURE DESCRIBED DOES NOT REFLECT THE 
MANUFACTURER (MILLENNIUMPHARMACEUTICALS, THE TAKEDA ONCOLOGY 
COMPANY) RECOMMENDATIONS FOR ADMINISTERING SUBCUTANEOUS 
BORTEZOMIB.
The procedure is based on evidence from the clinical literature and a survey of nurses as 
part of an academic project.
Pages: 22 (including references)
Rationale, Purpose and Outcomes:
The Cancer Clinics of Excellence (CCE) network is committed to delivering proven,
evidence-based treatment to people with cancer. This evidence based treatment protocol (ETP)
provides Registered Nurses (RNs) with guidelines on the administration of subcutaneous
bortezomib (SCB). The guideline is based on evidence in the clinical literature on administration
of subcutaneous injections and from a survey of 43 nurses in the CCE network describing current
SCB injection techniques as well as their opinions about SCB.
Bortezomib (Velcade) is an effective treatment for patients with multiple myeloma
(Driscoll, Burris, & Annunziata, 2012). The subcutaneous (SC) route of administration has been
shown to be equally efficacious as the intravenous (IV) route, but with less peripheral
neuropathy (PN). Clinical studies and the package insert on SCB described the concentration for
preparing the drug and that the injections were administered in the abdomen and thigh (Arnulf et
al. 2012; Moreau et al. 2011; Moreau et al. 2012; Velcade 2012). A retrospective study of 15
patients suggested higher incidence of injection site reactions in the thigh than abdomen
(Kaminura et al. 2012). Studies of SCB and the package insert do not describe how the injections
were administered.
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The clinical literature is inconclusive on the best way to administer SC injections in 
general (Annersen & Willman, 2005). However, clinical studies have shown needle size, angle 
of injection, use of an air bubble and giving injections over 10 to 30 seconds have resulted in 
decreased bruising, site reactions and increased patient satisfaction (Birkebaek, Solvig, 
Jorgensen, Smedegaard, & Christiansen, Frid et al. 2010; Gibney, Arce, Bryon & Hirsch, 2010; 
Gill & Prausnitz, 2007; Moore et al. 2010; Wooldridge & Jackson, 1988; Zaybak & Korshid
2007).
A 2013 survey of 43 CCE RNs who had administered SCB suggested there is agreement 
that SCB is more convenient than IVB and nurses believe patients prefer SCB to IVB. There 
were differences in techniques used and generally strong agreement that a practice guideline 
would be beneficial and would be followed by CCE nurses.
The purpose for a guideline is to provide RNs at CCE with a standardized method for 
administering SCB. The expected outcome of implementation and adoption of a practice 
guideline by oncology RNs is to specifically impact the nursing sensitive outcomes of patients 
with multiple myeloma. Nursing sensitive patient outcomes (NSPO) are those outcomes that can 
be influenced directly by nursing interventions (Given & Sherwood, 2005). Oncology NSPOs 
that may be realized with consistent SC injection techniques include:
Table 11 Nursing Sensitive Patient Outcomes and Measures
Outcome Measures
Symptom control and management • Lower incidence of peripheral 
neuropathy
• Reduced injection site reactions and 
pain
Functional status • Completion of effective treatment 
length of therapy
Psychological health status • Reduced discomfort and anxiety
associated with injection and treatment
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• Patient perception about treatment 
Economics • Reduced clinic time
• Reduced cost
• Cost effective treatment compared to 
other treatment options
Responsible:
All RNs in the CCE network who administer bortezomib by the subcutaneous route to 
patients.
Abbreviations:
CCE Cancer Clinics of Excellence
ETP Evidence Based Treatment Protocol
IV Intravenous
IVB Intravenous bortezomib
NSPO Nursing Sensitive Patient Outcomes
RN Registered Nurse
SC Subcutaneous
SCB Subcutaneous bortezomib
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Guideline Procedure:
Graphics used with permission courtesy of Forum for Injection Technique (FIT) Canada 2013
Procedure Rationale and References
Verify order and appropriate dilution Bortezomib can be administered either by
the intravenous or subcutaneous route.
for the route of administration ordered. For subcutaneous route of
administration:
The volume of 0.9% sodium 
chloride used to reconstitute 
VELCADE for subcutaneous 
administration is less than the 
volume used for IV administration
— For 
subcutaneous 
reconstitution, add 1.4 mL 
of sterile 0.9% sodium 
chloride solution to the 
powder contained in the 
vial of VELCADE
— This 
reconstitution will result in 
a final concentration of 2.5 
mg/mL VELCADE
— The 
reconstituted product 
should be a clear and 
colorless solution free of 
particulate matter
▼ Apply stickers to the vial and syringe 
that identify the intended route of 
administration
For intravenous route of administration:
The volume of 0.9% sodium 
chloride used to reconstitute 
VELCADE for IV adm in istration 
is greater than the volume used for 
subcutaneous administration
— For IV
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reconstitution, add 3.5 mL 
of sterile 0.9% sodium 
chloride solution to the 
powder contained in the
vial of VELCADE
— This 
reconstitution will result in 
a final concentration of 1 
mg/mL VELCADE
—  The 
reconstituted product 
should be a clear and 
colorless solution free of 
particulate matter
▼ Apply stickers to the vial 
and syringe that identify the 
intended route of administration
(Velcade package insert, 2012)
(Level of Evidence II)
2. Review procedure and rationale with
patient
3. Select appropriate site for Clinical studies only administered SCB
administration and rotation ( See in the abdomen and thigh, rotating
Figures 1, 2 and 3). If patient has had between sites with each injection
prior SCB injection(s), inspect prior (Moreau et al, 2011; Moreau et al. 2012;
site(s) and document current condition Arnulf et al. 2012). There is no data on
and patient report of previous administering SCB in the arm. One
injection(s) site(s) and experience(s). study reported more injection site
Inject at least 1 inch from prior injection reactions in the thigh than abdomen
sites with SCB (Kaminura et al. 2012). CCE
nurses indicated preference for using the 
abdomen. If only the abdomen is used, 
rotate the location to a different 
quadrant on the abdomen with every 
injection (See Figure 1). Within the 
quadrants on the abdomen, injections 
should be at least 1 inch from any prior 
injections (See Figure 2).
(Level of Evidence V)
Figure 1. Abdominal Injection Sites and Rotation
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Figure 2. Rotations within abdominal quadrants
Figure 3 Site Rotation Thighs
4. Place new needle on syringe Use of a dry needle ensures bevel has not
been dulled when inserted into the vial 
and eliminates tracking drug when 
inserting the needle into the skin (Agac 
& Gunes 2011)
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(Level of Evidence II)
5. Pull air into syringe to create an air 
bubble (See Figure 4). “Applying a fresh 
non-primed needle to the syringe with 
bortezomib, then drawing in an additional
0.5 to 1 mm of air, inverting the needle, 
and injecting” (Kurtin, 2013).
NOTE: This technique is never to be used 
with Intravenous injections.
Randomized studies with SC interferon 
and heparin have shown use of an air 
bubble (air sandwich) technique resulted 
in significantly less bruising, pain, and 
injection site reactions and improved 
patient satisfaction and compliance 
(Moore, 2007; Wooldridge & Jacson 
1988). The air sandwich technique has 
been recommended by the International 
Myeloma Foundation, and may prevent 
tracking drug when inserting and 
removing the needle (IMF, 2012; Kurtin, 
Knop & Milliron, 2012; Kurtin 2013; 
Kurtin S. n.d.; Murray et al. 2012)
(Level of Evidence III for Moore et al. & 
Wooldridge & Jackson. Level VII for 
Kurtin and IMF)
Subcutaneous Bortezomib 136
Figure 4 Air Bubble Technique
6. Wash hands, put on clean gloves, and Prevent contamination and cross
clean injection site
7. Pinch tissue with thumb and index 
finger (See Figures 5 and 6)
contamination from staff to patient 
(Hunter 2008)
Skin thickness does not vary 
significantly in adults, whereas 
subcutaneous adipose tissue does vary in 
different anatomical sites, between 
genders, with increased body mass index 
(BMI) and waist circumference (Akkus 
et al 2012; Gibney et al. 2010). Pinching
tissue helps ensure injection will be in 
adipose tissue and not into muscle. Using 
thumb and index finger may reduce 
grasping muscle tissue 
(Level of Evidence III)
Figure 5 Correct Skin Lift: Pinch Skin with Thumb and Forefinger
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Figure 6 Incorrect Skin Lift: Avoid Grasping Muscle Tissue
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8. Insert needle with smooth, steady 
motion using 45 degree angle when using 
a needle longer than 6 mm 
NOTE: Angle of insertion is dependent 
on needle length. (See Figures 6 and 57) 
Needle length Conversion:
4 mm = 5/32 inch
5 mm = 3/16 inch
6 mm = 1/4 inch 
8 mm = 5/16 inch
9.5 mm = 3/8 inch
12.7 mm = 1/2 inch
15.8 mm = 5/8 inch
There is consistency in describing 
the angle of insertion to ensure entering 
subcutaneous tissue rather than risking 
intramuscular (IM) injections based on 
needle size. A study of 388 adult 
diabetics demonstrated small needles, 
4mm to 6 mm in length, inserted at a 90 
degree angle without raising a skin fold 
will be in the SC tissue more than 98% 
of the time. Needles 6mm to 8 mm 
inserted at 90 degrees will result in IM 
injections 5% and 15% of the time. A 
12.7mm (1/2 inch) needle will result in 
IM injections 45% of the time when 
inserted at 90 degree angle and 21% of
the time when inserted at 45 degree 
angle (Gibney, Arce, Bryon, & Hirsch,
2010). A study of 499 subjects, including 
297 healthy controls, suggested the use of 
longer needles (> 6mm) without pinching 
the skin or inserting at a 90-degree angle 
might result in an IM injection (Akkus et 
al., 2012).
(Level of Evidence III)
Figure 7 Proper Injection Technique for 45 Degree Angle Insertion into Skin Lift. To be 
used with Needles Longer than 6 mm (1/4 inch)
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Figure 8 Proper Injection Technique for 90 Degree Angle Insertion into Skin Lift (depicted 
right). 90 degree angle is to be used with needles 6mm or shorter. 90 Degree Insertion 
without a skin lift (depicted left) may result in IM injection.
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9. Inject medication slowly over 10 - 30 
seconds. Use a minimum injection time of 
10 seconds per ml.
10. Wait briefly before withdrawing the 
needle.
Slow injections can reduce tissue damage 
caused by increased pressure. 
Experimental studies on SC injection 
duration demonstrated 30-second SC 
injections resulted in statistically 
significantly less pain and bruising than 
10-second injections (Akpinar & 
Celbioglu, 2007; Chan 2001; Zybak & 
Khorshid, 2007).
(Level of Evidence III)
Prevent backflow of medication. 
(Akpinary & Celebioglu, 2006; Hunter
2008)
(Level of Evidence IV)
11. Apply gentle pressure with dry
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gauze, and do not massage site.
12. Assess site.
13. Document site of administration in 
chart. Use anatomical site chart if 
available.
14. Instruct patient to report any 
unusual redness, swelling, warmth. 
Reinforce teaching on side effects to 
monitor and report.
Patient education about safety is a core 
professional role. Having oncology 
patients involved in preventing 
treatment errors and identifying adverse 
events results in trustful relationships 
(Schwappach, Hocreutener & Wernli 
2010).
(Level of Evidence VI)
Summary of guideline for administering SC bortezomib:
1. Use small gauge short needles.
2. Change the needle on the syringe before administering the injection.
3. Add an air bubble to the syringe to create an air sandwich.
4. Use a skin lift to ensure injection into adipose tissue.
5. Inject at a 45-degree angle into a skin lift for needles longer than 6mm (1/4 inch). A 90 
degree angle may be used into a skin lift for needles shorter than 1/4 inch.
6. Inject slowly, over 10 to 30 seconds.
7. Wait briefly before withdrawing the needle.
The techniques described in this guideline are based on evidence from the clinical literature. 
Levels of evidence are from Melnyk’s Hierarch of Evidence (Table 2).
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Table 2 Melnyk's Hierarch of Evidence (2005)
Description
Level of Evidence
I
II
III
IV
V
Evidence from a systematic 
review or meta-analysis of all 
relevant randomized controlled 
trials (RCT), or evidence -  based 
clinical practice guidelines based 
on systematic review of RCTs 
Evidence from at least one well- 
designed RCT
Evidence from well-designed 
controlled trials without 
randomization
Evidence from well designed case- 
controlled and cohort studies 
Evidence from systematic reviews 
of descriptive and qualitative 
studies
Strength
Strongest
VI Evidence from a single descriptive
or qualitative study
VII Evidence from the opinion of Weakest
authorities and/or reports of
expert committees
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